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A B S T R A C T
Background
Stroke is one of the leading causes of long-lasting disability and mortality and its global burden has increased in the past two decades.
Several therapies have been proposed for the recovery from, and treatment of, ischemic stroke. One of them is citicoline. This review
assessed the benefits and harms of citicoline for treating patients with acute ischemic stroke.
Objectives
To assess the clinical benefits and harms of citicoline compared with placebo or any other control for treating people with acute ischemic
stroke.
Search methods
We searched in the Cochrane Stroke Group Trials Register, CENTRAL, MEDLINE Ovid, Embase Ovid, LILACS until 29 January 2020. We
searched the World Health Organization Clinical Trials Search Portal and ClinicalTrials.gov. Additionally, we also reviewed reference lists
of the retrieved publications and review articles, and searched the websites of the US Food and Drug Administration (FDA) and European
Medicines Agency (EMA).
Selection criteria
We included randomized controlled trials (RCTs) in any setting including participants with acute ischemic stroke. Trials were eligible for
inclusion if they compared citicoline versus placebo or no intervention.
Data collection and analysis
We selected RCTs, assessed the risk of bias in seven domains, and extracted data by duplicate. Our primary outcomes of interest were all-
cause mortality and the degree of disability or dependence in daily activities at 90 days. We estimated risk ratios (RRs) for dichotomous
outcomes. We measured statistical heterogeneity using the I2 statistic. We conducted our analyses using the fixed-eQect and random-
eQects model meta-analyses. We assessed the overall quality of evidence for six pre-specified outcomes using the GRADE approach.
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Main results
We identified 10 RCTs including 4281 participants. In all these trials, citicoline was given either orally, intravenously, or a combination of
both compared with placebo or standard care therapy. Citicoline doses ranged between 500 mg and 2000 mg per day. We assessed all the
included trials as having high risk of bias. Drug companies sponsored six trials.
A pooled analysis of eight trials indicates there may be little or no diQerence in all-cause mortality comparing citicoline with placebo (17.3%
versus 18.5%; RR 0.94, 95% CI 0.83 to 1.07; I2 = 0%; low-quality evidence due to risk of bias). Four trials showed that citicoline may not
increase the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo, according to the
Rankin Scale (21.72% versus 19.23%; RR 1.11, 95% CI 0.97 to 1.26; I2 = 1%; low-quality evidence due to risk of bias).
Meta-analysis of three trials indicates there may be little or no diQerence in serious cardiovascular adverse events comparing citicoline
with placebo (8.83% versus 7.77%; RR 1.04, 95% CI 0.84 to 1.29; I2 = 0%; low-quality evidence due to risk of bias). Overall, either serious or
non-serious adverse events – central nervous system, gastrointestinal, musculoskeletal, etc. – were poorly reported and harms may have
been underestimated.
Four trials suggested that citicoline results in no diQerence in functional recovery, according to the Barthel Index, compared with placebo
(32.78% versus 30.70%; RR 1.03, 95% CI 0.94 to 1.13; I2 = 24%; low-quality evidence due to risk of bias). Citicoline may not increase the
proportion of patients with a minor impairment (according to ≤ 1 scores in the National Institutes of Health Stroke Scale) (5 trials, 24.31%
versus 22.44%; RR 1.08, 95% CI 0.96 to 1.21; I2 = 27%, low-quality evidence due to risk of bias). None of the included trials reported data
on quality of life.
A pre-planned Trial Sequential Analysis suggested that no more trials may be needed for the primary outcomes.
Authors' conclusions
This review assessed the clinical benefits and harms of citicoline compared with placebo or any other standard treatment for people with
acute ischemic stroke. The findings of the review suggest there may be little to no diQerence between citicoline and its controls regarding
all-cause mortality, disability or dependence in daily activities, functional recovery, neurological function and severe adverse events, based
on low-certainty evidence. None of the included trials assessed quality of life and the safety profile of citicoline remains unknown. The
available evidence is of low quality due to either limitations in the design or execution of the trials.
P L A I N   L A N G U A G E   S U M M A R Y
Citicoline for treating people with acute ischemic stroke
Review question
What is the clinical benefit and harm of citicoline compared with placebo or other standard treatment for treating people with acute
ischemic stroke?
Background
Acute ischemic stroke is defined as a sudden episode of disturbance of brain function caused by a blockage in the blood vessels of the
brain. It is the leading cause of long-lasting disability and the second major cause of death. Citicoline is a substance that may prevent the
death of brain cells located close to the area of brain damage.
Search date
Searching was completed on 29 January 2020
Study characteristics
We included randomized controlled trials, both published and unpublished. We did not apply any limitation by language, country, or study
design. We included people (adults or children) with acute ischemic stroke irrespective of the underlying cause. Stroke was based on
the clinical diagnosis confirmed with brain scans. We included trials that compared citicoline with placebo, usual care, or other usual
treatment.
Key results
We identified 10 relevant trials that included 4281 participants; six trials were carried out in multiple centers and two were international.
We considered most trials to be at high risk of bias and they included small numbers of participants. This raises the risk of over-estimating
benefits and under-estimating harms. Trials tested citicoline given either by mouth or by injection. Citicoline did not seem to influence
death or disability in daily activities, severe side-eQects, functional recovery, or neurological recovery.
Quality of the evidence
Risks of bias, imprecision, and outcome reporting bias all make the quality of evidence low. None of the included trials reported data on
quality of life. Researchers poorly reported harms caused by citicoline, so the profile of harms remains unclear.
Citicoline for treating people with acute ischemic stroke (Review)








































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Citicoline compared with placebo or standard treatment for treating people with acute ischemic stroke
Citicoline compared with placebo or no intervention for treating people with acute ischemic stroke
Patient or population: people with acute ischemic stroke
Settings: either inpatients or outpatients
Intervention: citicoline


















All-cause mortality (at any time of trial)
Follow-up: 6 to 12 weeks









Disability or dependence in daily activities
Patients with moderate or lower degree of
disability or dependence (according to < 3
scores in the modified Rankin scale)
lower scores indicate better outcome
Follow-up: 6 weeks









Severe adverse events 
Follow-up: 6 weeks









sponds to pooled analy-
sis for the risk of severe
cardiovascular adverse
events. Trials reported
number of adverse events
instead of number of par-
ticipants with adverse
events. See Analysis 1.14.
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Patients with scores in the Barthel Index ≥ 95
points
Follow-up: 6 weeks
Ghosh 2015 reported it
with a range of points (85
to 100)
Neurological function
Patients with minor impairment (according to
≤ 1 scores in the National Institutes of Health
Stroke Scale)
Follow-up: 6 weeks









Quality of life (at the time of follow-up) See comment See comment Not estimable - See comment No trials assessed this out-
come
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aAssumed risk is based on median control group risks in the meta-analysis.
bDowngraded 2 levels for limitations in design and execution: 88% (7/8) of the trials assessing this outcome had high risk for allocation, and 38% (3/8) showed high risk for attrition
bias for this outcome.
cDowngraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 50% (2/4) showed high risk for attrition
bias, and 75% (3/4) had high risk for detection bias for this outcome.
dDowgraded 2 levels due to high risk of bias and imprecision (small number of events).
eDowngraded 2 levels for limitations in design and execution: 75% (3/4) of the trials assessing this outcome had high risk for allocation, and 75% (3/4) showed high risk for
detection bias for this outcome.
fDowngraded 2 levels for limitations in design and execution: 80% (4/5) of the trials assessing this outcome had high risk for allocation, and 40% (2/5) showed high risk for attrition
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B A C K G R O U N D
Description of the condition
Stroke is one of the leading causes of long-lasting disability and
mortality (Martynov 2015; Yan 2017). The global burden of stroke
has increased in the past two decades (Hankey 2017). In 2015,
ischemic heart disease and stroke were the two leading causes of
premature mortality worldwide, and the leading causes of years of
life lost (YLLs) in 119 countries and territories (Wang 2016). Finding
a safe, inexpensive therapy to prevent and treat stroke is becoming
an area of interest in international public health.
Stroke is defined as an acute (sudden) episode characterized
by clinical signs of focal or global disturbance of cerebral
(brain) function caused by infarction (blockage in blood flow) or
spontaneous hemorrhage (bleeding) in the relevant part of the
brain, retina, or spinal cord, lasting more than 24 hours, or of
any duration if imaging (computed tomography [CT]; or magnetic
resonance imaging [MRI]) or autopsy show focal infarction or
hemorrhage relevant to the symptoms. By comparison, a transient
ischemic attack (TIA) is defined as a focal dysfunction of less than
24 hours' duration and with no imaging evidence of infarction
(Hankey 2017; Portegies 2016). Stroke is classified into ischemic
stroke (obstruction of cerebral blood), intracerebral hemorrhage
(a focal collection of blood within the brain parenchyma or
ventricular system that is not caused by trauma), and subarachnoid
hemorrhage (bleeding into the subarachnoid space). Ischemic
stroke is the most prevalent type and accounts for 75% to 85% of
all strokes (Cassella 2017; Martynov 2015). This Cochrane Review
focused on acute ischemic stroke.
DiQerent strategies have been proposed for the recovery from,
and treatment of, ischemic stroke. During the first few hours
of onset of an ischemic stroke, blood flow can be restored
through mechanical thrombus extraction (thrombectomy) or by
intravenous thrombolysis with the administration of recombinant
tissue plasminogen activators (rt-PA) that break down blood clots.
However, only 5% to 20% of people with acute ischemic stroke
are treated with thrombolysis or thrombus extraction, or both
(Martynov 2015; Wardlaw 2014).
Three parenchymal vascular states are seen in people with acute
ischemic stroke, namely: the ischemic core; the zone of penumbra
adjacent to it; and the region of benign oligemia adjacent to
that (Manning 2014). The ischemic penumbra region is defined
as the "zone of nonfunctioning but still viable tissue that may
recover its function if blood flow can be restored for example,
by therapeutic intervention" (Astrup 1981; Astrup 1982). The
penumbra region represents that portion of the ischemic territory
that is still potentially salvageable, and so it is the target of
all acute therapies (Hillis 2015; Manning 2014; Martynov 2015).
Therefore, the zone of penumbra must be protected; this protection
is called neuroprotection. In this scenario, neuroprotection has
been defined as "administering therapy as rapidly as possible
following the onset of symptoms in an eQort to minimize cerebral
infarction while the ischemic brain is awaiting reperfusion" (Patel
2017). There are pharmacological and non-pharmacological forms
of neuroprotection (Patel 2017; Wang 2017), and this Cochrane
Review focused on one type of pharmacological neuroprotector:
citicoline.
Several studies have suggested that citicoline is eQective for
treating central nervous system disorders (CNS), including acute
and chronic cerebral ischemia, intracerebral hemorrhage, global
cerebral hypoxia, and neurodegenerative diseases (Martynov
2015). These studies claim that citicoline treatment reduces
size of infarct (region of dead tissue), decreases free fatty
acid concentration, decreases neurologic deficits, restores
animal learning performance, reduces glutamate-mediated injury,
preserves phosphatidylcholine levels, and improves neuronal
survival (Clark 2009).
Description of the intervention
Citicoline is the generic name for cytidine 5'-diphosphocholine
(CDP-choline). Citicoline is the combination of two molecules:
cytidine and choline. These molecules cross the blood-brain
barrier separately; a]er reaching the brain cells they combine
to generate CDP-choline (Martynov 2015). Thus, it is a natural
endogenous compound and a precursor for the synthesis of
phosphatidylcholine, one of the components of cell membranes.
During cerebral ischemia, phosphatidylcholine is broken down into
free fatty acids and free radicals that increase the likelihood of
ischemic injury (Clark 2009).
Citicoline is synthesized in oral and enteral formulations for
clinical practice. Citicoline is a water-soluble compound, and
pharmacokinetic studies on healthy adults have shown an optimal
absorption of both oral and intravenous doses. Once absorbed,
citicoline is converted to choline and cytidine, which circulate in the
body, enter systemic circulation and cross the blood–brain barrier
for resynthesis into citicoline in the brain (Clark 2009). Citicoline
has been administered intravenously at doses ranging between 500
mg and 2000 mg respectively in randomized controlled trials (RCTs)
(Avarez-Sabín 2013; Clark 1997).
How the intervention might work
The cytidine-5'-diphosphocholine (CDP-choline or citicoline)
pathway begins with the uptake of exogenous choline into the
cell, followed by diQerent enzymatic reactions that lead to the
synthesis of phosphatidylcholine. The hypothesized mechanism
of action assumes that citicoline undergoes hydrolysis and
dephosphorylation to yield cytidine and choline products. These
breakdown products then enter the brain separately and act as
substrates for the resynthesis of CDP-choline. This mechanism is
believed to slow down phospholipid breakdown and accelerate
phospholipid resynthesis, which are necessary for membrane
repair (Grieb 2014). Citicoline is a free radical scavenger that
reduces the availability of free radicals a]er acute ischemic
episodes (Rajah 2017), and so may slow the damage. It may
facilitate recovery by activating neurogenesis, synaptogenesis,
and angiogenesis (creation of brain cells, gaps between them,
and blood supply), and enhances neurotransmitter metabolism.
In an animal model, administration of citicoline showed an up-
regulation of synaptophysin in the penumbra region that could
indicate an increase of synaptic (brain) activity (Martynov 2015).
The administration of citicoline increases brain choline, and
accelerates the synthesis of phosphatidylcholine, decreases
levels of free fatty acids, and reduces the generation of free
radicals. Overall, the administration of citicoline may protect
cell membranes by reducing phosphatidylcholine breakdown
(Martynov 2015). Recent research suggests that citicoline may
Citicoline for treating people with acute ischemic stroke (Review)
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enhance endogenous brain plasticity and repair even when it is
administered several hours a]er the ischemic event (Clark 2009;
Overgaard 2014). An animal study reported significantly improved
motor and functional recovery in the citicoline-treated group at the
end of a 28-day intervention period, when citicoline was given 24
hours a]er middle cerebral artery stroke, and taken for 28 days
(Clark 2009).
Why it is important to do this review
This Cochrane Review is important because controversy exists
regarding the clinical eQectiveness of citicoline for treating people
with acute stroke. Some randomized placebo, or head-to-head,
controlled clinical trials and meta-analyses suggest limited or no
clinical benefits (Clark 1999; Clark 2001; ECCS- AIS 2012; ICTUS
2012; Secades 2016; Shi 2016), while other randomized, placebo-
controlled clinical trials report beneficial eQects (Alviarez 2007;
Clark 1997; Tazaki 1988). Furthermore, Dávalos 2002, Secades 2016,
and Shi 2016 have several methodological limitations such as
lack of reporting summary of finding tables, use of odds ratio
instead of risk ratio, and use of cumulative meta-analysis (Sterne
2001), instead of Trial Sequential Analysis (TSA) (Wetterslev 2017).
Regarding odds ratio, there are several publications opposed to
the use of odds ratio in conducting systematic reviews (Altman
1998; Barnes 1998; Bland 2000; Davies 1998; Higgins 2019; Sackett
1996). In addition, drug companies have funded many trials
(Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; ICTUS 2012),
and it is necessary to assess the eQectiveness of the drug
independently (Lundh 2017). Argentina, Austria, Chile, Indonesia,
Mexico, Portugal, Thailand, and Venezuela prescribe citicoline
(Chen 2016). Since 17 April 2009, citicoline has been banned in the
USA and Canada (Chen 2016; FDA 2019). Conducting a systematic
review according to Cochrane methodology is fundamental to
identify the clinical benefits and harms of citicoline compared with
placebo or any other control for treating people with acute ischemic
stroke.
O B J E C T I V E S
To assess the clinical benefits and harms of citicoline compared
with placebo, any other drug or usual care for treating people with
acute ischemic stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) irrespective of
publication status. We did not apply any limitation by language,
country, or duration of follow-up. We only included parallel-design
trials.
Types of participants
People (children or adults) with acute ischemic stroke, irrespective
of etiology. We used clinical diagnosis with imaging as an eligibility
criterion.
Types of interventions
We included trials that compared citicoline with placebo, usual
care, or other interventions.
Citicoline administered at any dose, by any route, and for
any duration of treatment, versus no intervention, placebo,
or other interventions. Since acute ischemic stroke requires a
variety of medical treatments (that is, primary interventions),
we considered citicoline as a supplementary intervention. Thus,
for the purpose of this review, eligible RCTs were those that
compared the same primary interventions with and without
citicoline supplementation.
Types of outcome measures
Primary outcomes
• All-cause mortality (at 90 days).
• Degree of disability or dependence in daily activities according
to the modified Rankin scale (at 90 days) (Harrison 2013;
McArthur 2014; van Swieten 1988). See Appendix 1.
Secondary outcomes
• Adverse events during the first 30 days, assessed according to
recommendations from Lineberry 2016.
• Functional recovery: assessed with the Barthel Index (at 90 days)
(Harrison 2013; Mahoney 1965). See Appendix 2 for details.
• Neurological function assessed with the National Institutes of
Health Stroke Scale (NIHSS) (Harrison 2013). We assessed this at
the first 24 hours (acute phase), at 72 hours, and at discharge.
See Appendix 3 for details.
• Quality of life (at 90 days): assessed using the 36-item Short
Form Survey (SF-36), EuroQol, the Stroke Specific Quality of Life
scale (SS-QoL) (Harrison 2013).
The timing of outcome measures indicates the approximate target
for the review. It is based on the conventional timing used in the
assessment of these outcomes.
Search methods for identification of studies
See the methods for the Cochrane Stroke Group Specialised
register. We searched for trials in all languages and arranged for
translation of relevant articles where necessary.
Electronic searches
We searched in the Cochrane Stroke Group Trials Register and the
following electronic databases.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2020,
Issue 1) in the Cochrane Library (searched 29 January 2020)
(Appendix 4)
• MEDLINE Ovid (from 1948 to 29 January 2020) (Appendix 5)
• Embase Ovid (from 1974 to 29 January 2020) (Appendix 6)
• LILACS (Latin American and Caribbean Health Science
Information database; 1982 to 29 January 2020) Appendix 7
With the assistance of the Cochrane Stroke Group's Information
Specialist, we designed the search strategy in MEDLINE and
adapted it to all other databases (Appendix 5). We combined all
search strategies deployed with subject strategy adaptations of
the Highly Sensitive Search Strategy designed by Cochrane for
identifying randomized controlled trials and controlled clinical
trials (as described in the Cochrane Handbook for Systematic
Reviews of Interventions Chapter 6: Lefebvre 2011).
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Searching other resources
We also searched the following ongoing trials registries.
• US National Institutes of Health Ongoing Trials Register
(www.ClinicalTrials.gov) (Appendix 8)
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/en) (Appendix 9)
• Stroke Trials Registry (www.strokecenter.org/trials)
In order to identify unpublished information submitted for the
marketing approval of citicoline, we also searched the following
sites.
• Food and Drug Administration (www.fda.gov) (Appendix 10);
• European Medicines Agency (www.ema.europa.eu/ema)
(Appendix 11).
We screened the reference lists of relevant studies and use Cited
Reference Search within Web of Science to identify further studies
for potential inclusion in the review, and we contacted trialists and
companies for further information.
Data collection and analysis
We conducted data collection and analysis of data according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011a; Higgins 2011b).
Selection of studies
Two  review authors (AMC, CV) independently screened titles
and abstracts of the references obtained as a result of our
searching activities, and excluded obviously irrelevant reports. We
retrieved the full-text articles for the remaining references and,
independently, two or more review authors (AMC, CV, IS) screened
the full-text articles and identified studies for inclusion. They also
identified and recorded reasons for exclusion of the ineligible
studies. We resolved any disagreements through discussion or, if
required, we consulted  a third review author (JMF). We collated
multiple reports of the same study so that each study, not each
reference, was the unit of interest in the review. We recorded the
selection process and completed a PRISMA flow diagram.
Data extraction and management
Two review authors (AMC, CV) independently extracted data from
included studies. We developed an Excel spreadsheet based on
the 'Data extraction template for included studies' from the
Consumers and Communication Group resources for authors. We
planned to describe the details of the intervention following
recommendations from HoQmann 2014 and HoQmann 2017.
Assessment of risk of bias in included studies
Two review authors (AMC, CV) independently assessed risk of bias
for each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011c). We resolved
any disagreements by discussion or by involving another review
author (JMF, XB). We assessed the risk of bias according to the
following domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other bias
We graded the risk of bias for each domain as high, low, or unclear
and provide information from the study report together with a
justification of our judgment in the 'Risk of bias' tables.
We included company funding, bias in the presentation of the data,
design bias, measurements and confounding biases under 'Other
bias'. See Porta 2014 for definitions of the examples of biases.
See Appendix 12 for details of domains.
Measures of treatment e=ect
For binary outcomes in this review, such as all-cause mortality
and adverse events, we calculated the risk ratio (RR) with 95%
confidence intervals (CIs).
For future updates we will follow this approach: for continuous
outcomes, such as functional outcome, degree of disability or
dependence in daily activities, and neurological, behavioral and
cognitive function, we plan to calculate the mean diQerence
(MD) with 95% CI. If ordinal data are reported, we will use a
proportional odds model as a measure of treatment eQect with
Stata statistical so]ware (STATA) (Bath 2012: Deeks 2017; Scott
1997). If diQerent scales are used for measuring the same outcome,
for example quality of life, we plan to use the standardized mean
diQerence (SMD) with 95% CI. We will also estimate ratio of
means (RoM) with 95% CI from mean diQerence (Friedrich 2011).
Due to practitioners' understanding and preferring dichotomous
presentations of continuous outcomes, which they perceive to be
the most useful (Johnston 2016), we will estimate odds ratios (OR)
with 95% CI and the number needed to treat for an additional
beneficial outcome (NNTB) from SMD with Furukawa's method
(Furukawa 1999; Furukawa 2011).
As recommended in section 9.2.3.2 of the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a), if necessary we
will multiply the mean values from one set of studies by −1 to ensure
that all the scales point in the same direction (Deeks 2017).
If statistical information is missing (such as standard deviations),
we will try to extract them from other relevant information in the
paper, such as P values and CIs.
We will calculate the NNTB if the RR was significant (P value <
0.05). NNTB is a measure of assessment of clinical useful of the
consequences of treatment (Laupacis 1988). We will estimate NNTB
with GraphPad so]ware and with the Cochrane Stroke Group NNT
calculator. If ordinal data are reported, we will estimate NNTB
according to Bath 2011.
Unit of analysis issues
The unit of analysis was participants. We excluded cluster RCTs.
As recommended in the Cochrane Handbook for Systematic Reviews
of Interventions, we conducted the following plan to assess the
outcomes with multiple observations.
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• For primary outcomes (all-cause mortality and degree of
disability or dependence in daily activities according to the
modified Rankin scale) and secondary outcomes (adverse
events, functional recovery and quality of life), we selected a
single time point and analyzed only data at this time for trials in
which it will be presented.
• Neurological function assessed with the National Institutes
of Health Stroke Scale (secondary outcome): we planned to
define diQerent periods of follow-up (short-term, medium-term,
and long-term follow-up) (Deeks 2017), and perform separate
analyses.
Dealing with missing data
We assessed the percentage of dropouts for each intervention
group for each included trial, and evaluated whether an intention-
to-treat (ITT) analysis was performed or could have been performed
from the available published information. We contacted study
authors to resolve any questions arising from this issue.
In order to undertake an ITT analysis, we sought data from the
trial authors about the number of participants in treatment groups,
irrespective of their compliance and whether or not they were later
thought to be ineligible, otherwise excluded from treatment, or lost
to follow-up. If this information was not forthcoming, we performed
a 'per protocol' analysis of those who completed the study, being
aware that it may be biased.
We included participants with incomplete or missing data in
sensitivity analyses by imputing them according to the following
scenarios (Hollis 1999).
• Extreme case analysis favoring the experimental intervention
('best-worse' case scenario): none of the drop-outs/participants
lost from the experimental arm, but all of the drop-outs/
participants lost from the control arm experienced the outcome,
including all randomized participants in the denominator.
• Extreme case analysis favoring the control ('worst-best' case
scenario): all drop-outs/participants lost from the experimental
arm, but none from the control arm experienced the outcome,
including all randomized participants in the denominator.
• Gamble-Hollis analysis, which takes account of the uncertainty
and generates uncertainty intervals for a trial incorporating both
sampling error and the potential impact of missing data (Gamble
2005). This method increases the uncertainty of the trials
using the results from the best-case and worst-case analyses
(Chaimani 2014).
Assessment of heterogeneity
We quantified statistical heterogeneity using the I2 statistic, which
describes the percentage of total variation across trials that is due
to heterogeneity rather than sampling error (Higgins 2003). We had
set an I2 threshold greater than 60% to consider the presence of
statistical heterogeneity (Deeks 2017).
Assessment of reporting biases
We did not identify 10 or more RCTs to conduct the assessment of
reporting biases for any outcome. For the future update, therefore,
we will use the contour-enhanced funnel plot to diQerentiate
asymmetry that is due to publication bias from that due to other
factors (Peters 2008). We will assess likelihood of publication bias
with Harbord's and Peters' tests (Sterne 2011). We will use Stata
statistical so]ware to produce conventional and contour funnel
plots (STATA).
Data synthesis
We performed meta-analyses with 95% CI using either a fixed-eQect
or random-eQects model. For future updates, in case of statistical
heterogeneity (I2 > 60%), we will report data using the random-
eQects model and prediction interval (Deeks 2017; IntHout 2016;
Riley 2011). We conducted meta-analysis with Review Manager 5
(Review Manager 2014).
Trial sequential analysis (TSA)
We applied trial sequential analysis (TSA), as cumulative meta-
analyses are at risk of producing random errors due to sparse data
and repetitive testing of the accumulating data (Brok 2008; Brok
2009; Imberger 2015; Imberger 2016; Thorlund 2010; Wetterslev
2008; Wetterslev 2009; Wetterslev 2017). To minimize random
errors, we calculated the required information size (i.e. the number
of participants needed in a meta-analysis to detect or reject a
certain plausible intervention eQect) (Wetterslev 2008; Wetterslev
2017). The required information size calculation also accounted
for the heterogeneity or diversity present in the meta-analysis
(Wetterslev 2008; Wetterslev 2009; Wetterslev 2017). We used
the event proportion in the control group; assumption of a
plausible RR reduction of 20% or the RR reduction observed in
the included trials with low risk of bias; a risk of type I error of
5%; a risk of type II error of 10%; and the empirical diversity of
the meta-analysis for estimating the diversity-adjusted required
information size (Wetterslev 2009; Wetterslev 2017). We added
the trials according to the year of publication. On the basis of
the required information size, we constructed trial sequential
monitoring boundaries (Lan 1983; Thorlund 2011a; Wetterslev
2008). These boundaries determined the statistical inference one
may draw regarding the cumulative meta-analysis that has not
reached the required information size. If the trial sequential
monitoring boundary for benefit or harm is crossed before the
required information size is reached, further trials may turn out
to be superfluous. On the other hand, if the boundary is not
surpassed, it is probably necessary to continue conducting trials in
order to detect or reject a certain intervention eQect. This can be
determined by assessing whether the cumulative Z-curve crosses
the trial sequential boundaries for futility. If futility boundaries are
crossed, then further trials may be unnecessary (CTU 2011). We
conducted TSA using so]ware from the Copenhagen Trial Unit (CTU
2011; Thorlund 2011a). We did only for the primary outcomes: all-
cause mortality and degree of disability or dependence in daily
activities according to the modified Rankin scale.
GRADE and 'Summary of findings' table
We developed a 'Summary of findings' table with the following
outcomes: all-cause mortality; degree of disability or dependence
in daily activities on the modified Rankin scale; adverse events;
functional recovery (Barthel Index); neurological function (National
Institutes of Health Stroke Scale: NIHSS); and quality of life
(Summary of findings 1). We assessed the quality of the evidence
for each outcome according to GRADE domains (study limitations,
consistency of eQect, imprecision, indirectness and publication
bias) (Atkins 2004). We used methods and recommendations
described in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Schünemann 2011a), and
GRADEpro GDT so]ware (GRADEpro GDT 2015). We justified all
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decisions to downgrade the quality of the evidence using footnotes,
and we made comments to aid the reader's understanding of the
review where necessary. We calculated the assumed control group
risks using the median control group risk (Schünemann 2011b).
Subgroup analysis and investigation of heterogeneity
We conducted the following subgroup analysis for primary
outcomes if more than five trials were included.
• Trials supported by pharmaceutical companies versus trials
without support by pharmaceutical companies.
• Trials with low risk of bias versus trials with high risk of bias.
• Trials with small sample size (≤ 200 participants) versus trials
with large sample size (> 200 participants).
Due to lack of data, we were not able to conduct subgroup analysis
with:
• participants with diabetes mellitus versus participants without
diabetes mellitus;
• participants with high blood pressure versus participants
without high blood pressure.
Sensitivity analysis
We performed sensitivity analysis for primary outcomes with Stata
statistical so]ware (STATA), in order to explore the influence
of particular factors on the intervention eQect size: 'best-worst
case' scenario versus 'worst-best case' scenario and Gamble-Hollis
analysis (Gamble 2005).
Bayes factors
We estimated the threshold for clinical relevance for primary
outcomes through use of Bayes factors (Jakobsen 2014). The Bayes
factor is a likelihood ratio that indicates the relative strength of
evidence for two theories (Dienes 2014; Dienes 2018 Goodman
1999; Goodman 2005). The Bayes factor is a comparison of how
well two hypotheses (the null hypothesis ‒ H0; and the alternative
hypothesis - H1) predict the data (Goodman 1999). The Bayes factor
provides a continuous measure of evidence for H1 over H0. When
the Bayes factor is 1, evidence is insensitive, and this means that the
data are equally well predicted by both models and the evidence
does not favor either model over the other (1 means the data are
as well predicted by H1 as H0, so it should not be interpreted as
favoring H0; rather the evidence does not point either way). As
the Bayes factor increases above 1 (towards infinity) the evidence
favors H1 over H0. As the Bayes factor decreases below 1 (towards
0) the evidence favors H0 over H1 (Dienes 2008; Dienes 2014; Dienes
2018).
Despite the use of Bayes factors, we based the conclusions of
this Cochrane Review on the Review Manager 5 analysis (Review
Manager 2014).
R E S U L T S
Description of studies
Results of the search
The search yielded 1410 references, of which we deemed 18 to
be potentially eligible on the basis of title and abstract. Ten trials
involving 4543 participants met our inclusion criteria (Alviarez 2007;
Clark 1997; Clark 1999; Clark 2001; Ghosh 2015; Guillen 1995; ICTUS
2012; Seifaddini 2017; Tazaki 1988; Warach 2000). The evidence is
current to 29 January 2020. See Figure 1 for details of the flow
diagram with the search results and selection of studies.
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Figure 1.   -Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
The trials are described in Characteristics of included studies. Trials
varied in size as well as in the characteristics of the included
participants, duration of intervention, and drug dosage.
Methods
Between 1988 and 2017 (29 years), 10 trials were conducted in
nine countries: Canada (Clark 2001), Germany (ICTUS 2012), India
(Ghosh 2015), Iran (Seifaddini 2017), Japan (Tazaki 1988), Portugal
(ICTUS 2012), Spain (ICTUS 2012; Guillen 1995), USA (Warach 2000;
Clark 1997; Clark 1999; Clark 2001), and Venezuela (Alviarez 2007).
There were two international trials (ICTUS 2012; Clark 2001). The
number of the centers ranged between 1 and 118. There were six
multicenter trials: Warach 2000 (N = 16); ICTUS 2012 (N = 59), Tazaki
1988 (N = 63); Clark 1997 (N = 21); Clark 1999 (N = 31); and Clark 2001
(N = 118). Six trials reported the duration of follow-up, which ranged
between 1 and 12 weeks (Clark 1997; Clark 1999; Clark 2001; Ghosh
2015; ICTUS 2012; Warach 2000). Nine trials had two comparison
groups (Alviarez 2007; Clark 1999; Clark 2001; Ghosh 2015; Guillen
1995; ICTUS 2012; Seifaddini 2017; Tazaki 1988; Warach 2000), while
one trial had four arms (Clark 1997). All trials reported the duration
of treatment, which ranged between 1 and 12 weeks (Alviarez 2007;
Clark 1997; Clark 1999; Clark 2001; Ghosh 2015; Guillen 1995; ICTUS
2012; Seifaddini 2017; Tazaki 1988; Warach 2000). ICTUS 2012 tested
for superiority, while the rest of the trials specified no type of
test. ICTUS 2012 and Seifaddini 2017 stated the timing for starting
citicoline treatment, which remains unknown for the other trials.
ICTUS 2012 reported during the first 24 hours a]er the onset of
symptoms. Seifaddini 2017 noted post-24 hours a]er the onset of
symptoms.
Participants
The trials randomized 4543 participants (mean: 450.3; median: 179;
minimum: 40; maximum: 2298). Four trials reported missing data
whose percentages of missing outcome data ranged between 1.8%
and 19.6% (mean: 13.45%; median: 16.5%) (Alviarez 2007; ICTUS
2012; Tazaki 1988; Warach 2000).
Eight trials reported the age of participants (Alviarez 2007; Clark
1997; Clark 1999; Clark 2001; ICTUS 2012; Seifaddini 2017; Tazaki
1988; Warach 2000). In six trials, the mean age of participants
was 69.27 years old (standard deviation [SD]: 2.05, and median
was 68.86) in the citicoline groups while the mean age in the
placebo groups was 70.54 years old (SD: 2.02 and median was 70.69)
(Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; ICTUS 2012;
Warach 2000). Seifaddini 2017 reported that 84.3% and 93.75%
of the participants were 40 or more years old in the citicoline
and placebo groups, respectively. Tazaki 1988 stated that 91% and
96.32% of participants were between 50 and 90 years old in the
citicoline and placebo groups, respectively.
Eight trials reported the sex of participants (Alviarez 2007; Clark
1997; Clark 1999; Clark 2001; ICTUS 2012; Seifaddini 2017; Tazaki
1988; Warach 2000). The average percentage of male participants
who received citicoline was 57.34 (median: 54.5) versus a mean of
50.28 (median 48.6) in the placebo group.
The description of the relevant clinical variables of the participants
varied across the trials. Five trials included participants with
a history of TIA (Alviarez 2007; Clark 1999; Clark 2001; ICTUS
2012; Warach 2000), three trials reported a history of stroke or
TIA (ICTUS 2012; Clark 1997; Clark 2001), five trials reported
participants with diabetes (Alviarez 2007, Clark 1997; Clark 2001;
ICTUS 2012; Seifaddini 2017), six trials fixed participants with
blood hypertension (Alviarez 2007; Clark 1997; Clark 1999; Clark
2001; ICTUS 2012; Seifaddini 2017), two trials recorded participants
with a history of smoking (Alviarez 2007; Clark 1997), one trial
noted a history of hyperlipidemia (Seifaddini 2017), and three trials
included participants with a history of cardiac disorders (Clark
1997; Clark 2001; ICTUS 2012).
Of the 10 included trials, all reported the inclusion criteria (Alviarez
2007; Clark 1997; Clark 1999; Clark 2001; Ghosh 2015; Guillen 1995;
ICTUS 2012; Seifaddini 2017; Tazaki 1988; Warach 2000), and nine
stated the exclusion criteria (Alviarez 2007; Clark 1997; Clark 1999;




Nine trials used citicoline alone as the experimental group (Alviarez
2007; Clark 1997; Clark 1999; Clark 2001; Guillen 1995; ICTUS 2012;
Seifaddini 2017; Tazaki 1988; Warach 2000). One trial combined
citicoline with standard stroke therapy (Ghosh 2015).
The route of administration of citicoline varied across the included
trials: combined i.e. either intravenously or orally (Alviarez 2007;
Ghosh 2015; ICTUS 2012), intravenous only (Guillen 1995; Seifaddini
2017; Tazaki 1988), and oral (Clark 1997; Clark 1999; Clark
2001; Warach 2000). The daily total dose of citicoline by any
administration route was not similar across the trials ‒ 500 mg,
1000 mg, 2000 mg, and 3000 mg. The duration of administration
and the daily total dose of citicoline used by intravenous route was
dissimilar: 1000 mg by seven days (Seifaddini 2017), 1000 mg by
14 days (Tazaki 1988), 2000 mg during three days (Alviarez 2007;
ICTUS 2012), 2000 mg by five days (Ghosh 2015), and 3000 mg by
10 days (Guillen 1995). Thus, the range of duration of intravenous
administration was three to 14 days. Likewise, the duration of
administration and the daily total dose of citicoline used by oral
route varied: 500 mg for six weeks (Clark 1997; Clark 1999; Warach
2000), 1000 mg during six weeks (Alviarez 2007; Warach 2000), 1000
Citicoline for treating people with acute ischemic stroke (Review)









Cochrane Database of Systematic Reviews
mg during three weeks (Ghosh 2015), 2000 mg by six weeks (Clark
1997; Clark 2001; ICTUS 2012).
Control group
Eight trials used placebo as the control group (Alviarez 2007;
Clark 1997; Clark 1999; Clark 2001; ICTUS 2012; Seifaddini 2017;
Tazaki 1988; Warach 2000). Three trials stated that appearance was
identical and indistinguishable between the comparison groups
(Clark 1999; ICTUS 2012; Tazaki 1988). One trial used physiological
saline as placebo (Tazaki 1988). Two trials used standard or
conventional therapy as control group (Ghosh 2015; Guillen 1995).
One trial described the composition of standard stroke therapy
used as control (Ghosh 2015).
Co-intervention
Three trials reported using co-interventions (Alviarez 2007; ICTUS
2012; Tazaki 1988). Two trials described the type of co-intervention
(Alviarez 2007; ICTUS 2012); but only one trial reported use of
intravenous thrombolysis (ICTUS 2012).
Outcomes
The mean of the number of the outcomes was 4.6 (range: 1 to 9).
Six trials stated which were primary or secondary outcomes (Clark
1997; Clark 1999; Clark 2001; Ghosh 2015; ICTUS 2012; Warach
2000). Of them, five trials selected relevant clinical outcomes as
the primary option (Clark 1997; Clark 1999; Clark 2001; Ghosh
2015, ICTUS 2012). Four trials assessed the degree of disability or
dependence in daily activities according to the modified Rankin
scale (Alviarez 2007; Clark 1999; Clark 2001; ICTUS 2012). Seven
trials appraised the functional recovery with the Barthel Index
(Alviarez 2007; Ghosh 2015; Guillen 1995; ICTUS 2012; Clark 1997;
Clark 1999; Clark 2001). Four trials evaluated neurological function
with the National Institutes of Health Stroke Scale (NIHSS) (Clark
1999; Clark 2001; ICTUS 2012; Warach 2000). Three trials considered
all-cause mortality as a secondary outcome (Clark 1999; Clark 2001;
ICTUS 2012). One trial included adverse events as an outcome
(ICTUS 2012). Six trials included only one primary outcome (Clark
1997; Clark 1999; Clark 2001; Ghosh 2015; ICTUS 2012; Warach
2000), and one trial stated four primary outcomes (Seifaddini 2017).
Miscellaneous
Two trials reported the identifier trial number register (ICTUS 2012;
Seifaddini 2017). Five trials reported the trial conduct data (Clark
1997; Clark 1999; Clark 2001; ICTUS 2012; Tazaki 1988). Four trials
reported the sample size estimation a priori (Clark 1999; Clark
2001; ICTUS 2012; Warach 2000). One trial likely did a sample
size estimation before it started (Seifaddini 2017). Drug companies
supported six included trials (Alviarez 2007; Clark 1997; Clark 1999;
Clark 2001; ICTUS 2012; Warach 2000). It remained unknown in four
trials (Ghosh 2015; Guillen 1995; Seifaddini 2017; Tazaki 1988). One
trial declared the role of its sponsor (ICTUS 2012). Two trials clearly
stated financial disclosures (ICTUS 2012; Warach 2000). At least one
author of the following trials was an employee or consultant of the
drug company that sponsored the trial (Alviarez 2007; ICTUS 2012).
One trial stated an amendment of the protocol (Warach 2000).
There was no information in terms of the impact of the amendment
over the final results. This trial noted no trial number identifier.
One trial was stopped on the recommendation of the Data and
Safety Monitoring Board at the third interim analysis, because the
statistical stopping boundary for futility had been crossed (ICTUS
2012). This trial reported the trial identifier number.
Excluded studies
We excluded seven RCTs which were conducted without imaging
(Dereux 1987; Dereux 1987; ECCS- AIS 2012; Garcia Pastor 2004;
Goas 1980; Melnikova 2011; Panteleienko 2009). See Characteristics
of excluded studies.
Studies awaiting classification
We identified one study in this category (Hassan 2019).
Ongoing trials
We identified two ongoing trials (CTRI/2018/02/011900;
IRCT201601289014N90). See Characteristics of ongoing studies
table for details.
Risk of bias in included studies
We have summarized risks of bias in the included trials in Figure
2 and Figure 3, and we have provided more details in the
Characteristics of included studies table.
 
Figure 2.   Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Alviarez 2007 ? ? ? ? - + -
Clark 1997 ? ? ? ? + + -
Clark 1999 ? ? + ? + + ?
Clark 2001 ? ? + ? + + ?
Ghosh 2015 ? ? - - + - -
Guillen 1995 ? ? ? ? ? ? -
ICTUS 2012 + + + + - + -
Seifaddini 2017 ? ? ? ? ? - -
Tazaki 1988 ? ? + + + + -
Warach 2000 ? ? ? + - + -
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We rated one trial as having a low risk of selection bias because
the trial authors used a centralized randomization process with
an interactive voice response system (ICTUS 2012). Nine trials
had unclear risk of bias for this domain due to the lack of a
clear description of how the random sequence generation was
conducted (Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; Ghosh
2015; Guillen 1995; Seifaddini 2017; Tazaki 1988; Warach 2000).
Allocation concealment
We considered risk of bias arising from the method of allocation
concealment to be low in one trial. This judgment is based on
the interactive voice response system used for reducing the risk
of selection bias (ICTUS 2012). Nine trials did not report the
randomization process methodology: thus, we considered risk of
bias arising from the method of allocation concealment to be
unclear (Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; Ghosh
2015; Guillen 1995; Seifaddini 2017; Tazaki 1988; Warach 2000).
Blinding
Blinding of participants and personnel (performance bias)
We rated risk of bias due to lack of blinding of participants and
personnel as low in four trials as they provide an appropriate
description of the blinding: the experimental drug and control were
indistinguishable, personnel were masked (Clark 1999; Clark 2001;
ICTUS 2012; Tazaki 1988). We judged five trials as unclear risk for
performance bias due to the absence of an adequate description for
blinding of participants and personnel (Alviarez 2007; Clark 1997;
Guillen 1995; Seifaddini 2017; Warach 2000). One trial had a high
risk of bias for this domain due to the following description: "the
authors evaluated the outcome themselves, were not blinded to
the treatment" (Ghosh 2015).
Blinding of outcome assessment (detection bias)
Three trials clearly reported outcome assessment as blinded, and
we considered detection bias to be low because the personnel
carrying out the clinical assessment were blinded (ICTUS 2012;
Tazaki 1988; Warach 2000). We rated six trials as having an unclear
risk of bias for blinding of outcome assessors due to lack of
information about the blinding of the personnel (Alviarez 2007;
Guillen 1995; Seifaddini 2017; Clark 1997; Clark 1999; Clark 2001).
We considered one trial to have a high risk of detection bias because
it did not report blinding for outcome assessment (Ghosh 2015).
Incomplete outcome data
We rated risk of attrition bias as low in five trials (Clark 1997;
Clark 1999; Clark 2001; Ghosh 2015; Tazaki 1988). Two trials had
an unclear risk of bias for this domain: one trial reported no
information about this because it was published as an abstract,
whereas the other trial assessed physiological outcomes (Guillen
1995: Seifaddini 2017). We considered three trials as having a high
risk of bias for attrition bias due to the percentage of dropouts,
which were 16%, 23% and 19%, respectively (Alviarez 2007; ICTUS
2012; Warach 2000)
Selective reporting
We considered seven trials as having a low risk for selective
outcome reporting bias due to reported information about the
prefixed outcomes for this Cochrane Review. That information
allowed us to pool the data (Alviarez 2007; Clark 1997; Clark 1999;
Clark 2001; ICTUS 2012; Tazaki 1988; Warach 2000). We considered
one trial as having an unclear risk of bias for this domain; trial
information was reported in an abstract (Guillen 1995). We judged
two trials as having a high risk of reporting bias because neither
appropriate data about outcomes nor information about outcomes
required in this Cochrane Review were available (Ghosh 2015;
Seifaddini 2017). Two trials reported their trial registration number
(ICTUS 2012; Seifaddini 2017).
Other potential sources of bias
We detected bias either in the presentation of the data or in
the design of trials (Alviarez 2007; Ghosh 2015; Guillen 1995;
Seifaddini 2017; Tazaki 1988, Clark 1997), in the measurements and
confounding biases due to lack of information regarding the impact
of the amendment of the trial protocol (Warach 2000), funding
bias due to many trial authors receiving either consultation fees or
honoraria from the trial sponsor, and one trial author was a full-
time employee of the sponsor (Alviarez 2007; ICTUS 2012; Clark
1997). We considered two trials as having an unclear risk for other
potential sources of bias (funding bias) (Clark 1999; Clark 2001).
Based on the protocol for this Cochrane Review, which stated
"We will consider trials at low risk of bias to be those that used
an adequate system to generate their allocation sequence, had
adequate allocation concealment, adequate blinding, adequate
handling of incomplete outcome data, were free of selective
outcome reporting and were free of other bias", we considered all
trials to have a high risk of bias.
E=ects of interventions
See: Summary of findings 1 Citicoline compared with placebo or
standard treatment for treating people with acute ischemic stroke
The results are based on 4281 randomized participants in nine
trials (Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; Ghosh
2015; Guillen 1995; ICTUS 2012; Tazaki 1988; Warach 2000). One
included trial only supplied information about hemodynamic
cerebral outcomes (Seifaddini 2017). All trials compared citicoline
versus placebo or no intervention. Table 1 shows a summary
of meta-analyses with 95% CI comparing the fixed-eQect with




A pooled analysis of eight trials found no diQerence in all-cause
mortality comparing citicoline with placebo (399/2313 [17.3%]
versus 379/2049 [18.5%]; RR fixed-eQect 0.94, 95% CI 0.83 to 1.07; I2
= 0%; low-quality evidence due to risk of bias) (Alviarez 2007; Clark
1997; Clark 1999; Clark 2001; Ghosh 2015; ICTUS 2012; Tazaki 1988;
Warach 2000) (Analysis 1.1). Bayes factor was 0.33 which means that
the evidence favors moderatelly null hypothesis over alternative
hypothesis. Trial Sequential Analysis suggested no more trials are
needed (Figure 4; Summary of findings 1).
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Figure 4.   Trial Sequential Analysis for citicoline versus placebo or no intervention on all-cause mortality. The
diversity-adjusted required information size (DARIS) was calculated based on an expected relative risk reduction
(RRR) of 14% from proportion event in control (Pc) group of 18.5% with an alpha of 5% and beta of 20%. Cumulative
Z-curve (blue line) reached futility area aKer seven trials, which means that no more trials are needed.
 
Subgroup analysis
Trials without support from pharmaceutical companies versus trials
supported by pharmaceutical companies
Two trials conducted without support from pharmaceutical
companies found no diQerence comparing citicoline with placebo
in terms of all-cause mortality (13/161 [8.07 %] versus 19/174 [10.91
%]: RR 0.78, 95% CI 0.41 to 1.49; I2 = 0%) (Ghosh 2015; Tazaki 1988).
Pooled data of six trials supported by pharmaceutical companies
showed no diQerence comparing citicoline with placebo in terms
of all-cause mortality (386/2152 [17.93 %] versus 360/1875 [19.2%]:
RR 0.95, 95% CI 0.83 to 1.08; I2 = 0%) (Alviarez 2007; Clark 1997;
Clark 1999; Clark 2001; ICTUS 2012; Warach 2000). Test for subgroup
diQerences: Chi2 = 0.34, df = 1 (P = 0.56), I2 = 0%. See Analysis 1.2.
Trials with ≤ 200 participants versus trials with > 200 participants
Pooled analysis of three trials which included 200 or fewer
participants showed no diQerence comparing citicoline with
placebo in terms of all-cause mortality (20/118 [16.94%] versus
17/122 [13.93%]: RR 1.26, 95% CI 0.70 to 2.29; I2 = 0%) (Alviarez 2007;
Ghosh 2015; Warach 2000). Pooled data of five trials which recruited
more than 200 participants showed no diQerence comparing
citicoline versus placebo in terms of all-cause mortality (379/2195
[17.26%] versus 362/1927 [18.78%]: RR 0.93, 95% CI 0.81 to 1.06; I2
= 0%) (Clark 1997; Clark 1999; Clark 2001; ICTUS 2012; Tazaki 1988).
Test for subgroup diQerences: Chi2 = 0.99, df = 1 (P = 0.32), I2 = 0%.
See Analysis 1.3.
Sensitivity analyses
Assessing the impact of missing outcome data
Meta-analysis of four trials not reporting missing data showed no
diQerence comparing citicoline versus placebo in terms of all-cause
mortality (159/942 [16.87%] versus 117/673 [17.38%]; RR 0.99, 95%
CI 0.79 to 1.23; I2 = 0%) (Clark 1997; Clark 1999; Clark 2001; Ghosh
2015). Pooled data of four trials reporting missing data showed
no diQerence comparing citicoline versus placebo in terms of all-
cause mortality (240/1371 [17.5%] versus 262/1376 [19.04%]; RR
0.92, 95% CI 0.78 to 1.07; I2 = 0%) (Alviarez 2007; ICTUS 2012; Tazaki
1988; Warach 2000). Test for subgroup diQerences: Chi2 = 0.28, df =
1 (P = 0.59); I2 = 0%. See Analysis 1.4.
Assessing the impact of the missing outcome data: best-case scenario
Pooling of four trials without missing data found no diQerence
between comparison groups in relation to all-cause mortality (RR
0.99, 95% 0.80 to 1.24; I2 = 0%) (Clark 1997; Clark 1999; Clark 2001;
Ghosh 2015). Meta-analysis of four trials reporting missing data
showed a reduction of 58% of the risk of all-cause mortality with
citicoline use versus placebo use (RR 0.42, 95% CI 0.37 to 0.49; I2 =
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0%) (Alviarez 2007; ICTUS 2012; Tazaki 1988; Warach 2000). Test for
subgroup diQerences: Chi2 = 41.51, df = 1 (P < 0.00001); I2 = 97.6%.
See Analysis 1.5.
Assessing the impact of the missing outcome data: worst-case scenario
In relation to all-cause mortality a pool of four trials without missing
data found no diQerence between comparison groups (RR 0.99, 95%
0.79 to 1.23; I2 = 0%) (Clark 1997; Clark 1999; Clark 2001; Ghosh
2015). Meta-analysis of four trials reporting missing data found an
increase of 104% of the risk of all-cause mortality in the citicoline
group compared with placebo (RR 2.04, 95% CI 1.79 to 2.332; I2 =
0%) (Alviarez 2007; ICTUS 2012; Tazaki 1988; Warach 2000). Test for
subgroup diQerences: Chi2 = 41.51, df = 1 (P < 0.00001); I2 = 97.6%.
See Analysis 1.6.
Assessing the impact of the missing outcome data: the Gamble-Hollis
analysis
With regard to all-cause mortality, pooling four trials without
missing data found no diQerence between comparison groups (RR
0.99, 95% 0.79 to 1.23; I2 = 0%) (Clark 1997; Clark 1999; Clark
2001; Ghosh 2015). Meta-analysis of four trials found no diQerence
between comparison groups (RR 0.86, 95% CI 0.45 to 1.64; I2 =
0%) (Alviarez 2007; ICTUS 2012; Tazaki 1988; Warach 2000). Test for
subgroup diQerences: Chi2 = 0.15, df = 1 (P = 0.70); I2 = 0%. See
Analysis 1.7.
Degree of disability or dependence in daily activities
Citicoline versus placebo
Four trials showed that citicoline may not increase the proportion
of patients with a moderate or lower degree of disability or
dependence compared with placebo, according to the Rankin Scale
(414/1906 [21.7%] versus 339/1762 [19.2%]; RR fixed-eQect 1.11,
95% CI 0.97 to 1.26; I2 = 1%; low-quality evidence due to risk of bias)
(Alviarez 2007; Clark 1999; Clark 2001; ICTUS 2012) (Analysis 1.8).
Bayes factor was 1.81 which means that the evidence anecdotally
favors alternative hypothesis over null hypothesis. Trial Sequential
Analysis suggested no more trials are required (Figure 5; Summary
of findings 1).
 
Figure 5.   Trial Sequential Analysis for citicoline versus placebo or no intervention on degree of disability or
dependence in daily activities according to the modified Rankin scale. The diversity-adjusted required information
size (DARIS) was calculated based on an expected relative risk reduction (RRR) of 19% from proportion event in
control (Pc) group of 19.95% with an alpha of 5% and beta of 20%. Cumulative Z-curve (blue line) reached futility
area aKer four trials, which means that no more trials are needed.
 
Subgroup analysis
Trials with ≤ 200 participants versus trials with > 200 participants
One trial with 200 or fewer participants found no diQerence in
the proportion of patients with a moderate or lower degree of
disability or dependence compared with placebo, according to the
Rankin Scale (13/38 [34.2%] versus 10/39 [25.6%]; RR 1.33, 95%
CI 0.67 to 2.67) (Alviarez 2007). A meta-analysis including three
trials that included 200 or more participants showed no diQerence
comparing citicoline with placebo in the proportion of patients with
a moderate or lower degree of disability or dependence (401/1868
[34.2%] versus 329/1723 [25.6%]; RR 1.10, 95% CI 0.96 to 1.25; I2
= 27%) (ICTUS 2012; Clark 1999; Clark 2001). Test for subgroup
diQerences: Chi2 = 0.29, df = 1 (P = 0.59); I2 = 0%. See Analysis 1.9.
Citicoline for treating people with acute ischemic stroke (Review)









Cochrane Database of Systematic Reviews
Sensitivity analysis
Assessing the impact of missing outcome data
Meta-analysis of two trials which did not report missing data
showed no diQerence comparing citicoline with placebo in the
proportion of patients with a moderate or lower degree of disability
or dependence compared with placebo, according to the Rankin
Scale (190/720 [23.4%] versus 121/573 [21.1%]; RR 1.23, 95% CI
1.01 to 1.50; I2 = 0%) (Clark 1999; Clark 2001). Pooled data of two
trials that reported missing data found no diQerence comparing
citicoline versus placebo in the proportion of patients with a
moderate or lower degree of disability or dependence (224/1186
[18.9%] versus 218/1189 [18.3%]; RR 1.03, 95% CI 0.87 to 1.22; I2 =
0%) (Alviarez 2007; ICTUS 2012). Test for subgroup diQerences: Chi2
= 1.74, df = 1 (P = 0.19); I2 = 42.4%. See Analysis 1.10.
Assessing the impact of missing outcome data: best-case scenario
According to a best-case scenario assessment of the impact of
missing data, there was no diQerence in two trials which did not
report missing data comparing citicoline with placebo regarding
the proportion of patients with a moderate or lower degree of
disability or dependence compared with placebo, according to the
Rankin Scale (RR 1.23, 95% CI 1.00 to 1.50; I2 = 0%) (Clark 1999;
Clark 2001). By contrast, meta-analysis of two trials that reported
missing data showed that citicoline may result in a slight reduction
in the proportion of patients with a moderate or lower degree of
disability or dependence compared with placebo (RR 0.44, 95% CI
0.39 to 0.51; I2 = 67%) (Alviarez 2007; ICTUS 2012). Test for subgroup
diQerences: Chi2 = 67.32, df = 1 (P < 0.00001); I2 = 98.5%. See Analysis
1.11.
Assessing the impact of missing outcome data: worst-case scenario
According to a worst-case scenario assessment of the impact of
missing data, there was no diQerence in two trials which did not
report missing data comparing citicoline with placebo regarding
the proportion of patients with a moderate or lower degree of
disability or dependence compared with placebo, according to the
Rankin Scale (RR 1.23, 95% CI 1.00 to 1.50; I2 = 0%) (Clark 1999; Clark
2001). Pooled data of two trials reporting missing data showed that
citicoline may result in an increase in the proportion of patients
with a moderate or lower degree of disability or dependence
compared with placebo (RR 2.33, 95% CI 2.03 to 2.69; I2 = 0%)
(Alviarez 2007; ICTUS 2012). Test for subgroup diQerences: Chi2 =
26.45, df = 1 (P < 0.00001); I2 = 96.2%. See Analysis 1.12.
Assessing the impact of missing outcome data: the Gamble-Hollis
analysis
An assessment of the impact of missing outcome data according the
Gamble-Hollis analysis showed no diQerence comparing citicoline
with placebo in the proportion of patients with a moderate or lower
degree of disability or dependence compared with placebo, neither
in trials which did not report missing data (RR 1.23, 95% CI 1.00 to
1.50; I2 = 0%) (Clark 1999; Clark 2001), nor in those reporting missing
data (RR 1.14, 95% CI 0.54 to 2.42; I2 = 0%) (Alviarez 2007; ICTUS
2012). Test for subgroup diQerences: Chi2 = 0.03, df = 1 (P = 0.86); I2





Pooled analyses either with three or two trials found no diQerence
comparing citicoline versus placebo in terms of the following severe
adverse events.
• Cardiovascular (RR 1.04, 95% CI 0.84 to 1.29; 299 events, 3591
participants; I2 = 0%; low-quality evidence due to risk of bias and
imprecision (Clark 1999; Clark 2001; ICTUS 2012).
• Central nervous system (including hemorrhagic or ischemic
stroke) (RR 1.30, 95% CI 1.07 to 1.59; 406 events, 3591
participants; I2 = 93%; low-quality evidence due to risk of bias
and imprecision (ICTUS 2012; Clark 1999; Clark 2001).
• Respiratory (including pneumonia) (RR 1.01, 95% CI 0.78 to 1.31;
406 events, 3591 participants; I2 = 0%; low-quality evidence due
to risk of bias and imprecision (Clark 1999; Clark 2001; ICTUS
2012).
• Gastrointestinal (RR 0.64, 95% CI 0.40 to 1.00; 65 events, 1370
participants; I2 = 69%; low-quality evidence due to risk of bias
and imprecision (Alviarez 2007; Clark 1999; Clark 2001).
• Musculoskeletal (RR 1.52, 95% CI 0.50 to 4.60; 15 events, 1293
participants; I2 = 0%; low-quality evidence due to risk of bias and
imprecision (Clark 1999; Clark 2001).
• Renal and urologic disorders (RR 2.04, 95% CI 0.99 to 4.22; 39
events, 1560 participants; I2 = 0%; low-quality evidence due to
risk of bias and imprecision (Clark 1999; Clark 2001; Tazaki 1988).
• Hematological disorders (RR 1.27, 95% CI 0.46 to 3.51; 16 events,
1560 participants; I2 = 0%; low-quality evidence due to risk of
bias and imprecision (Clark 1999; Clark 2001; Tazaki 1988).
Test for subgroup diQerences: Chi2 = 12.54, df = 7 (P = 0.08); I2 =
44.2%. See Analysis 1.14. Summary of findings 1.
One trial reporting severe hepatic dysfunction showed no
diQerence between comparison groups (RR 1.47, 95% CI 0.48 to
4.49; 7 events, 267 participants; I2 = 0%; low-quality evidence due
to risk of bias and imprecision (Tazaki 1988).
Non-severe adverse events
One trial including 2298 participants supplied data regarding non-
severe adverse events (ICTUS 2012). There was no diQerence
between comparison groups regarding cardiac disorders (RR 0.94,
95% CI 0.82 to 1.08; 572 events), pyrexia (RR 1.02, 95% CI 0.87 to
1.19; 512 events), constipation (RR 1.03, 95% CI 0.88 to 1.20; 484
events), urinary tract infections (RR 1.06, 95% CI 0.89 to 1.26; 426
events), headache (RR 0.96, 95% CI 0.79 to 1.18; 314 events), nausea
and vomiting symptoms (RR 0.95, 95% CI 0.77 to 1.16; 315 events),
agitation (RR 1.20, 95% CI 0.94 to 1.54; 229 events), hemorrhagic
transformation of the stroke (RR 0.98, 95% CI 0.74 to 1.29; 184
events), pneumonia (RR 1.02, 95% CI 0.73 to 1.41; 135 events), and
hypotension (RR 0.92, 95% CI 0.63 to 1.36; 100 events). See Analysis
1.15. We rated the quality of evidence for non-severe adverse events
as low due to risk of bias and imprecision.
Table 2 shows the information about harms as reported in the trials.
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Functional recovery
Citicoline versus placebo
One trial assessing functional recovery with the a cut-oQ in the
Barthel Index of 50 points found no diQerence comparing citicoline
with placebo (16/38 [42.1%] versus 13/39 [33.3%]; RR fixed-eQect
1.26, 95% CI 0.71 to 2.26; low-quality evidence due to risk of
bias and imprecision) (Alviarez 2007). Four trials assessing the
functional recovery with a cut-oQ in the Barthel Index of 95 or
more points found no diQerence comparing citicoline with placebo
(676/2062 [32.8%] versus 549/1788 [30.7%]; RR 1.03, 95% CI 0.94 to
1.13; I2 = 24%; low-quality evidence due to risk of bias). The Bayes
factor was 0.75 which means that the evidence favors moderatelly
the null hypothesis over the alternative hypothesis (Clark 1997;
Clark 1999; Clark 2001; ICTUS 2012). One trial with a cut-oQ in
the Barthel Index of 85 to 100 points found no diQerence favoring
citicoline versus placebo (10/28 [35.7%] versus 4/35 [11.4%]; RR
3.13, 95% CI 1.10 to 8.91; low-quality evidence due to risk of bias
and imprecision) (Ghosh 2015). Test for subgroup diQerences: Chi2
= 4.69, df = 2 (P = 0.10), I2 = 57.3%. See Analysis 1.16. Summary of
findings 1.
Based on a P value < 0.05, Guillen 1995 reported improvements of
functional recovery in a narrative way.
Neurological function
Citicoline versus placebo
Five trials assessed neurological function with the National
Institutes of Health Stroke Scale at a cut-oQ point of ≤1 points. A
pooled analysis of these trials showed that citicoline, compared
to placebo, may not increase the proportion patients with minor
impairment (514/2114 [24.3%] versus 412/1836 [22.4%]; RR fixed-
eQect 1.08, 95% CI 0.96 to 1.21; I2 = 27%; low-quality evidence due
to risk of bias). The Bayes factor was 1.32 which means that the
evidence anecdotally favors the alternative hypothesis over the null
hypothesis (Clark 1997; Clark 1999; Clark 2001; ICTUS 2012; Warach
2000). See Analysis 1.17. Summary of findings 1.
Quality of life
Citicoline versus placebo
None of the trials reported information about this outcome. See
Summary of findings 1.
D I S C U S S I O N
Summary of main results
This Cochrane Review about citicoline for treating people with
acute ischemic stroke includes 10 trials randomizing 4281
participants. These trials evaluated citicoline that was given orally,
intravenously or both compared with placebo or standard care
therapy. Citicoline doses ranged between 500 and 2000 mg per day.
Four out of 10 trials reported an a priori sample size estimation.
Drug companies sponsored six trials. There were six multicenter
trials, of which two were international. Trials were conducted
in nine countries in either outpatient (ambulatory) or inpatient
settings. Overall, we assessed these trials as having a high risk
of bias. The main results yielded from the meta-analysis are as
follows.
• None of the pooled analyses found diQerences between
citicoline and their comparison groups regarding all-cause
mortality, disability or dependence (according to < 3 scores
in the modified Rankin scale), functional recovery (assessed
with the Barthel Index), neurological impairment (according to
≤ 1 scores in the National Institutes of Health Stroke Scale),
or severe adverse events. Quality of evidence for eQects of
interventions was low due to either limitations in the design
and execution of the trials or very low number of events and
smallness of sample sizes.
• One trial reporting information about non-severe adverse
events identified no diQerences. The quality of evidence was low
due to high risk of bias and a very low number of events. Table
2 shows how such harmful events were reported in the included
trials.
• Two trials pooled not using the Barthel Index at a cut-oQ point of
50 points or a cut-oQ point of 85 to 100 points found no diQerence
between comparison groups and the evidence was of low quality
due to high risk of bias and very low number of events and
smallness of sample sizes.
• No trial assessed the eQects of interventions over the quality of
life.
See Summary of findings 1 for details.
Overall completeness and applicability of evidence
This Cochrane Review has not found evidence that citicoline is
useful for treating people with acute ischemic stroke. Although
there were no trials at low risk of bias, this statement is based on
either sensitivity analyses or subgroup analyses from trials that
included a broad range of participants with diQerent co-morbidities
who received diQerent treatment approaches. Furthermore, the
Trial Sequential Analyses for citicoline versus placebo or no
intervention showed that no more studies are required for
assessing either all-cause mortality or degree of disability or
dependence in daily activities according to the modified Rankin
scale.
Only 40% of the trials included in this Cochrane Review reported
sample size estimation a priori (Clark 1999; Clark 2001; ICTUS 2012;
Warach 2000), which coincides with findings by other researchers
(Chan 2008; Mhaskar 2012). Therefore, the clinical significance of
the trials without a sample size estimation is uncertain (Alviarez
2007; Clark 1997; Ghosh 2015; Guillen 1995; Tazaki 1988). Also, these
trials reported no threshold for detecting diQerences between
comparison groups, which is a component for estimating the
sample size (Mascha 2018; Sormani 2017).
Table 3 provides details related to the sample size, number of
outcomes, and conclusions of the included trials in this Cochrane
Review (Alviarez 2007; Clark 1997; Clark 1999; Clark 2001; Ghosh
2015; Guillen 1995; ICTUS 2012; Seifaddini 2017; Tazaki 1988;
Warach 2000). Another pitfall found in the included trials is that
one out of six trials that did not do a formal estimation of sample
size reported two or more outcomes (Table 3), which could yield
an increasing risk of false positives and false negatives: family-
wise error rate (Delorme 2016; Senn 2007; van der Laan 2004).
By using Trial Sequential Analysis this review has determined an
optimal information size providing suQicient protection to reduce
overestimation or random errors (Thorlund 2011b).
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We were not able to do show a meta-analysis about the adverse
events or harms with all the included trials. This could be for many
reasons: a lack of standardization of definitions and analyses of the
adverse events (Ioannidis 2014), the shortage of homogeneity and
plenty of variability in reporting harm data (Ioannidis 2009; Pitrou
2009), the diQerent times for conducting the trials (1988 to 2017),
and failure to collect the harm data (Allen 2018; Yang 2019). Table 2
shows how this issue was reported in each included trial.
Quality of the evidence
Summary of findings 1 shows the quality of evidence for
citicoline compared with placebo or standard treatment for
treating people with acute ischemic stroke. We considered the
quality of the evidence available for this comparison as low. This
was due to unclear risk of bias in almost all domains of the
trials for the outcomes assessed (all-cause mortality, degree of
disability or dependence in daily activities, functional recovery,
and neurological function). Due to limitations in design, execution,
and imprecision (small low number of events leading to wide
confidence intervals), the quality of evidence for serious adverse
events was rated as low.
Potential biases in the review process
Both outcome reporting and attrition biases act as information
suppressors, as does publication bias of any etiology (Ioannidis
2010). Based on this argument, the question arises: could the
amount of eQect of the intervention have been diQerent if the
percentage of those information suppressor biases had been
diQerent? It should be noted that there were three trials with loss of
information that fluctuated between 16% and 23% (Alviarez 2007;
ICTUS 2012; Warach 2000). Two of them were small trials, and
therefore low powered for detecting diQerences between citicoline
and the control groups (Alviarez 2007; Warach 2000). In addition,
two clinical trials supplied no information to the preset outcomes
of this Cochrane Review (Guillen 1995; Seifaddini 2017). If, on the
basis of not providing information to the outcomes of this Cochrane
Review, we had excluded two trials (Guillen 1995; Seifaddini 2017),
the eQect of the intervention would have been the same. This is
explained by the fact that none of them provided information about
the relevant pre-established clinical outcomes in this review. This
would have introduced publication bias, however, from which this
review is at low risk. This Cochrane Review rated 30% of trials as
having unclear or high risk of selective outcome reporting bias and
50% of trials as having unclear or high risk of attrition bias (Figure
2; Figure 3). This is a limitation which is described and reflected in
the quality of the evidence assessment (Summary of findings 1).
Agreements and disagreements with other studies or
reviews
Our results are similar to six non-Cochrane Reviews and pooled
analyses (Dávalos 2002; Lee 2010; Liu 2011; Saver 2002; Secades
2016; Shi 2016). We identified diQerences in their eligibility criteria
with respect to our Cochrane Review: 1) participants suQering
ischemic and hemorrhagic stroke (Lee 2010; Shi 2016); 2) inclusion
of non-RCTs (Lee 2010; Secades 2016); 3) use of diQerent scales
for assessing clinical benefits of citicoline (Secades 2016); 4) RCTs
with no imaging confirmation of stroke (Secades 2016; Shi 2016);
5) forest plot using the same placebo group three times in diQerent
subgroups for the same outcome (Shi 2016); and 6) use of odds ratio
for measuring treatment eQect (Dávalos 2002; Secades 2016; Shi
2016).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review assessed the clinical benefits and harms of citicoline
compared with placebo or any other standard treatment for people
with acute ischemic stroke. The findings of the review suggest
that, based on low-certainty evidence, there may be little to no
diQerence between citicoline and its controls regarding all-cause
mortality, disability or dependence in daily activities, functional
recovery, neurological function and severe adverse events. None of
the included trials assessed quality of life and the safety profile of
citicoline remains unknown.
Implications for research
The harms profile of citicoline remains unknown, because the
resulting evidence is of low quality due to limitations in the design
and execution of the trials, the very low number of events, and
the smallness of sample sizes, even a]er meta-analysis. The results
provided by the Trial Sequential Analysis methodology support
the conclusions of the best quality clinical trials included in this
Cochrane Review. The question is, is there a need for a new study
when none of the included RCTs reached the top line of statistical
significance; that is, the P value (alpha error), the fundamental
component for calculating the sample size? Even for the most
important primary outcome of this Cochrane Review, all-cause
mortality, the z-curve reached the area of futility with a cumulative
65% of the sample size estimation for Trial Sequential Analysis
(4345/6667). This Cochrane Review found no trial assessing quality
of life. We do not believe that this lack of information on the quality
of life outcome justifies a well-powered randomized controlled
trial comparing citicoline versus placebo in accordance with the
Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT 2013) and Consolidated Standards of Reporting Trials
(CONSORT 2010) recommendations.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods • Parallel design (2 arms)
• Multicenter study: no (1 center)
• International: no
• Country: Venezuela
• Treatment duration: 6 weeks
• Follow-up period: not reported
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not reported
Participants • Randomized: 77
• Citicoline group: 38
• Placebo group: 39
• Analyzed: 65
• Citicoline group: 31
• Placebo group: 34
• Age (likely mean; dispersion measure not described)
• Citicoline group: 69.23 (10.7)
• Placebo group: 70.38 (11.1)
• Sex (men, %):
• Citicoline group: 58.06 (18/31)
• Placebo group: 44.11 (15/34)
• National Institutes of Health Stroke Scale: not stated
• Stroke evolution time (likely mean; dispersion measure not described)
• Citicoline group: 6.1 (1.7) hours
• Placebo group: 6 (1.63) hours
• Systolic blood pressure (likely mean; dispersion measure not described)
• Citicoline group:156.13 (19.4) (mmHg)
• Placebo group: 154.74 (21.85) (mmHg)
• Diastolic blood pressure (likely mean; dispersion measure not described)
• Citicoline group: 96.03 (14.4) (mmHg)
• Placebo group: 95.88 (14.59) (mmHg)
• Blood hypertension
• Citicoline group: 59%
• Placebo group: 65%
• TIA
• Citicoline group: 35.5%
Alviarez 2007 
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• Placebo group: 41.6%
• Diabetes Mellitus
• Citicoline group: 13%
• Placebo group: 23.5%
• Smoking history
• Citicoline group: 5%
• Placebo group: 8.8%
• Inclusion criteria
• Any age
• Diagnosis of acute Ischemic stroke of middle cerebral artery origin, defined by neuroimaging stud-
ies with a time of evolution of less than 8 hours (therapeutic window)
• National Institutes of Health Stroke Scale ≥ 5 with at least 2 points in the motor sections
• Ambulatory and functionally independent before the accident
• Reliable in terms of taking the medication
• Informed consent accepted
• Exclusion criteria
• Intracerebral hemorrhage, or intraparenchymal cerebral hemorrhage
• Chronic liver disease
• Chronic kidney disease
• Chronic heart failure
• Patients taking clonidine, reserpine, methyldopa, antiepileptics, antidepressants or neuroleptics
• Patients with psychosis, brain tumor, vascular malformations, cardiac arrhythmias, toxic metabol-
ic encephalopathy
• Patients with recent or planned thrombolytic therapy
Interventions • Experimental: citicoline, 2000 mg, endovenous by day (2 × 500 mg ampoules) during 3 days. Then, 2
tablets (2 × 500 mg) oral/ twice during 6 weeks. No information was supplied regarding drug manu-
facture company
• Control: placebo (not described)
• Co-intervention: antiplatelet agent (acetylsalicylic acid, 325 mg, calcium channel blockers (90 mg),
vitamin E (400 mg)
Trial author stated no information about calcium channel blockers and vitamin E.
Treatment duration: 6 weeks.
Outcomes Outcomes were not classified as primary or secondary: degree of disability or dependence in daily ac-
tivities according to the modified Rankin scale, functional recovery assessed with the Barthel Index,
and neurological function assessed with the National Institutes of Health Stroke Scale (NIHSS), and
cerebral neuroimaging
Notes • Identifier trial number register: not stated
• Trial conduction dates: not given
• A priori sample estimation: no
• Financial disclosures: it was not stated tacitly or explicitly. However, 1 trial author had links with Lab-
oratorios Leti, S.A.V.
• Other disclosures: none
• Funding/support: not stated tacitly or explicitly
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were allocated in two groups: citicoline and placebo" (Page
128, translated from Spanish)
Alviarez 2007  (Continued)
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Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
There is imbalance between groups regarding transient cerebrovascular dis-
ease history, diabetes mellitus, and smoking history
Allocation concealment
(selection bias)
Unclear risk There was no mention about allocation concealment





Unclear risk Trial was reported as double blind but authors described no blinding ap-
proach
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Trial was reported as double blind but authors described no blinding ap-
proach




High risk Dropouts: 16% (12/77): deaths (N = 9)
Dropouts citicoline group: 3
Dropouts placebo group: 9
Selective reporting (re-
porting bias)
Low risk Trial authors reported clinically relevant endpoints







Methods • Parallel design (4 arms)
• Multicenter study: yes (21 centers)
• International: no
• Country: USA
• Treatment duration: 6 weeks
• Follow-up period: 6 weeks
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not stated
Participants • Enrolled and randomized: 259
• Citicoline (500 mg): 62
• Citicoline (1000 mg): 66
• Citicoline (2000 mg): 66
• Placebo: 65
• Age (year, mean)
• Citicoline (500 mg): 66
• Citicoline (1000 mg): 67
• Citicoline (2000 mg): 68
• Placebo: 70
Clark 1997 
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• Sex (men, %)
• Citicoline (500 mg): 48.38% (30/62)
• Citicoline (1000 mg): 53.03% (35/66)
• Citicoline (2000 mg): 40.90% (27/66)
• Placebo: 44.61% (29/61)
• Baseline National Institutes of Health stroke scale score (mean)
• Citicoline (500 mg): 11.6
• Citicoline (1000 mg): 13.2
• Citicoline (2000 mg): 13.6
• Placebo: 13
• Baseline Rankin scale value (mean)
• Citicoline (500 mg): 3.6
• Citicoline (1000 mg): 3.7
• Citicoline (2000 mg): 3.8
• Placebo: 3.6
• Blood hypertension (%)
• Citicoline (500 mg): 58
• Citicoline (1000 mg): 76
• Citicoline (2000 mg): 68
• Placebo: 66
• Previous stroke or TIA (%)
• Citicoline (500 mg): 18
• Citicoline (1000 mg): 26
• Citicoline (2000 mg): 38
• Placebo: 20
• Myocardial infarction previous (%)
• Citicoline (500 mg): 24
• Citicoline (1000 mg): 17
• Citicoline (2000 mg): 18
• Placebo: 37
• Diabetes
• Citicoline (500 mg): 23
• Citicoline (1000 mg): 33
• Citicoline (2000 mg): 39
• Placebo: 66
• Smoking (%)
• Citicoline (500 mg): 29
• Citicoline (1000 mg): 27
• Citicoline (2000 mg): 21
• Placebo: 23
• Inclusion criteria
• Focal neurologic deficit > 60 minutes
• Computerized tomography (or magnetic resonance imaging) compatible with clinical diagnosis or
acute stroke of middle cerebral artery origin
• National Institutes of Health stroke scale 2 with at least 2 points from section 5 and 6 (motor)
• Ambulatory and functionally independent prior to stroke
• Rankin scale score 52 pre-stroke
• Randomized within 24 hours of stroke
• Exclusion criteria
• Evidence of brain tumor or cerebral edema with subsequent effects
• Previous disorder that would impair interpretation of neurologic scales
Clark 1997  (Continued)
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• Neurologic signs and symptoms that improve during baseline screening
• Preexisting medical or psychiatric conditions that may interfere with suitability or participation
• Patients who require surgery
Interventions • Experimental: citicoline (tablets; 500 mg each). No information was supplied regarding drug manu-
facturer
• Citicoline (500 mg): 1 tablet (500 mg) once a day
• Citicoline (1000 mg): 1 tablet twice day
• Citicoline (2000 mg): 2 tablets twice day
• Treatment duration: 6 weeks
• Control: placebo. No information was supplied about taste or physical appearance regarding placebo
• Co-intervention: it was not stated
Outcomes • Primary:
• Functional outcome as determined by the Barthel Index (Barthel Index was classified into 5 strata:
death or zero, 5 to 40, 45 to 60, 65 to 80, 85 to 100).
• Secondary:
• Patients who had a favorable outcome (Barthel Index of 95 or 100 at 12 weeks)
• Differences between each dose level and placebo on the Modified Rankin scale
• Differences between each dose level and placebo on behavioral and cognitive function with use of
a neuropsychological test battery
• Differences between each dose level and placebo in the National Institutes of Health stroke scale
score, specifically the percentage of patients who had a favorable outcome, defined as a National
Institutes of Health stroke scale score of ≤ 1
• Number of days from stroke to hospital discharge
Notes • Identifier trial number register: not stated
• Trial conduction dates: June 1994 to August 1995
• A priori sample estimation: no
• Financial disclosures: it was not stated tacitly or explicitly. However, many trial authors had links to
Interneuron Pharmaceuticals Inc. 3 trial authors were paid scientific advisors to Interneuron Pharma-
ceuticals Inc
• Other disclosures: none
• Funding/support: it was not stated tacitly or explicitly
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "... were randomized ..." (page 673)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)





Unclear risk Quote: "... double-blind ..." (page 672)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Quote: "... double-blind ..." (page 672)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Clark 1997  (Continued)
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Low risk Trial authors reported clinically relevant endpoints






Methods • Parallel design (2 arms)
• Multicenter study: yes (31 centers)
• International: no
• Country: USA
• Treatment duration: 6 weeks
• Follow-up period: 6 weeks
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not stated
Participants • Enrolled and randomized: 394 (middle cerebral artery territory with National Institutes of Health
Stroke Scale)
• Citicoline (500 mg): 267
• Placebo: 127
• Age (year, mean)
• Citicoline (500 mg): 70
• Placebo: 71
• Sex (men, %)
• Citicoline (500 mg): 46
• Placebo: 49
• Time to treatment (hours, mean)
• Citicoline (500 mg): 11.7
• Placebo: 12.3
• Baseline National Institutes of Health stroke scale score (mean)
• Citicoline (500 mg): 11.6
• Placebo: 13
• Baseline Rankin scale value (mean): not reported
• Blood hypertension (%)
• Citicoline (500 mg):70
• Placebo: 72
• Previous stroke or TIA (%)
• Citicoline (500 mg): 35
• Placebo: 37
• Myocardial infarction previous: not reported
• Diabetes: not reported
• Smoking: not reported
• Inclusion criteria
Clark 1999 
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• Age ≥18 years
• Randomized within 24 hours of stroke
• Focal neurological deficit lasting at ≥ 60 minutes
• Computerized tomography (or magnetic resonance imaging) compatible with clinical diagnosis of
acute ischemic stroke
• Stroke clinically assessed to be in the middle cerebral artery territory
• National Institutes of Health stroke scale ≥ 5 with at least 2 points from sections 5 and 6 (motor)
• Ambulatory and functionally independent before stroke: Rankin scale score ≤ 2 (slight disability)
before stroke
• Exclusion criteria
• Computerized tomography (or magnetic resonance imaging) evidence of brain tumor, brain stem
or cerebellar infarction, subarachnoid hemorrhage, or primary intracerebral hemorrhage
• Severe coexisting systemic disease that limits life expectancy
• History of ventricular dysrhythmias, acute myocardial infarction, or any severe cardiovascular con-
dition that would interfere with participation: previous disorder which would impair interpretation
of neurological scales, neurological signs and symptoms that improve during baseline screening,
preexisting medical conditions that may interfere with participation
• Patients who require surgery within 24 hours
• Patients with recent or planned thrombolytic use
Interventions • Intervention: oral citicoline, 500 mg, likely once per day
• Control: oral placebo
• Co-intervention: not reported
• Treatment duration: 6 weeks
• Citicoline and placebo were a so]-gelatin capsule with identical appearance and consistency
Outcomes • Primary
• Functional outcome as determined by the Barthel Index at 12 weeks (the Barthel Index was classi-
fied into 5 strata (death or zero, 5 to 40, 45 to 60, 65 to 80, 85 to 100)
• Secondary
• Categorized Barthel Index at the other weeks
• Patients who had a full recovery (Barthel Index 95 or 100 at 12 weeks)
• Treatment differences on the Modified Rankin scale
• Treatment differences on neurological behavioral, and cognitive function by use of the NIHSS and
Mini-Mental State Examination
• Mortality
• Treatment differences in the percentage of patients who had a full recovery defined as an NIHSS
score of ≤ 1
• Number of days from stroke to hospital discharge
• Relative rate of improvement for the Barthel Index, Rankin scale, and National Institutes of Health
stroke scale between the groups. Additional post hoc outcome analyses were performed on a sub-
group of patients with moderate to large strokes
Notes • Identifier trial number register: not stated
• Trial conduction dates: from 30 June 1996 to 12 June 1997
• A priori sample estimation: yes
• Financial disclosures: no
• Other disclosures: no disclosures reported
• Funding/support: likely Interneuron Pharmaceuticals, Inc, Lexington, MA
Risk of bias
Bias Authors' judgement Support for judgement
Clark 1999  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomly assigned within each center with the use
of a blocked randomization" (Page 2593)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’. Trial au-
thors did not explain the procedure to obtain the "blocked randomization".
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’





Low risk Quote: "... either placebo or citicoline (500 mg) in a so]-gelatin capsule (identi-
cal in appearance and consistency)." (page 2593)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’







Low risk Trial authors reported relevant clinical outcomes





Methods • Parallel design (2 arms)
• Multicenter study: yes (118 centers)
• International: yes
• Country: USA and Canada
• Treatment duration: 6 weeks
• Follow-up period: 6 weeks
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): superiority
Participants • Randomized: 899
• Citicoline (2000 mg): 453
• Placebo: 446
• Received medication
• Citicoline (2000 mg): 453
• Placebo: 446
• Age (mean, years)
• Citicoline (2000 mg): 68
• Placebo: 67
• Sex (men, %)
• Citicoline (2000 mg): 50
• Placebo: 54
• Time to treatment (mean, hours)
Clark 2001 
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• Citicoline (2000 mg): 13.2
• Placebo: 13.3
• Received tissue plasminogen activator (%)
• Citicoline (2000 mg): 13
• Placebo: 11
• Baseline National Institutes of Health Stroke Scale Score
• Citicoline (2000 mg): 13 (median), 13.9 (mean)
• Placebo: 14 (median), 14.5 (mean).
• Hypertension
• Citicoline (2000 mg): 74
• Placebo: 70
• Previous stroke or TIA
• Citicoline (2000 mg): 31
• Placebo: 35
• Cardiac disease
• Citicoline (2000 mg): 49
• Placebo: 49
• Diabetes
• Citicoline (2000 mg): 25
• Placebo: 28
• Inclusion criteria
• Age 18 to 85 years
• Randomized within 24 hours of stroke
• Focal neurologic deficit lasting at least 60 minutes
• Computerized tomography (or magnetic resonance imaging) compatible with clinical diagnosis of
acute ischemic stroke
• Stroke clinically thought to be in the middle cerebral artery territory
• National Institutes of Health Stroke Scale 8 with at least 2 points from sections 5 and 6 (motor)
• Ambulatory and functionally independent prior to stroke with Rankin scale score 1 (no significant
disability) pre stroke
• Exclusion criteria
• Computerized tomography (or magnetic resonance imaging evidence of brain tumor, brainstem
or cerebellar infarction, significant cerebral edema, subarachnoid hemorrhage, or primary intrac-
erebral hemorrhage
• Severe co-existing systemic disease that limits life expectancy
• History of ventricular dysrhythmia, acute myocardial infarction, or severe cardiovascular condition
that would interfere with participation
• Previous disorder that would impair interpretation of neurologic scales
• Neurologic signs and symptoms that improve during baseline screening
• Pre-existing medical conditions that may interfere with participation
• Surgery required within 24 hours
• “OQ label” thrombolytic use; tissue plasminogen activator as approved for stroke was accepted
• Notable stroke lesions exclusively in the white matter, brainstem, cerebellum, or thalamus on stan-
dard radiologic assessments
• 1 of the clinical syndromes suggestive of lacunare infarcts
• Obtunded, presented with forced eye deviation, or total gaze paresis and dense hemiplegia as mea-
sured by the National Institutes of Health Stroke Scale
Interventions • Intervention: oral citicoline, 500 mg tablet, orally as 2 tablets twice daily. Total dose by day: 2000 mg
• Control: placebo
• Co-intervention: a nasogastric tube was placed for delivery of the study drug if patient was unable to
swallow
Clark 2001  (Continued)
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Participants should be inpatients at the start of the study medication treatment
Outcomes • Primary
• Improving from baseline on their National Institutes of Health Stroke Scale by 7 points at week 12
• Secondary
• Return to their pre-stroke Barthel index score at 12 weeks
• Improvement of 1 or 2 points on the Clinician’s Global Impressions scale at 12 weeks
• Improvement of ≥ 2 points on the Clinician’s Global Impressions severity scale at 12 weeks
• Mortality
• Differences at 12 weeks using an overall response analysis based on NIHSS improvement ≥ 7
• Barthel index return to pre-stroke values
• Clinician’s Global Impressions improvement of 1 or 2, and Clinician’s Global Impressions severity
improvement of ≥ 2
• Volume of ischemic lesions at week 12 on conventional T2-weighted magnetic resonance imaging
Notes • Identifier trial number: not stated
• Trial conduction dates: 3 August 1998 to 17 November 1999
• A priori sample estimation: yes
• Financial disclosures: no
• Other disclosures: no other disclosures reported
• Funding/support: likely Interneuron Pharmaceuticals, Inc, Lexington, MA
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomly allocated within each center using a
blocked randomization ..." and "Patients were randomly allocated and strati-
fied into two categories ..." (Page 1597)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)





Low risk Quote: "The sites were not aware of the patient’s group assignment." (Page
1597)
Intervention and placebo were identical in appearance and consistency (Page
1597)
Blinding of outcome as-
sessment (detection bias)
All outcomes







Low risk Trial reported information about relevant clinical outcomes
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Study characteristics
Methods • Parallel design (2 arms)
• Multicenter study: no (1 center)
• International: no
• Country: India
• Treatment duration: 30 days
• Follow-up period: 90 days
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not reported
Participants • Randomized: 100
• Citicoline group: 50
• Control group: 50
• 63 participants were diagnosed having ischemic stroke.
* Citicoline: 28
* Control: 35
The trial authors did not describe age, sex, baseline National Institutes of Health Stroke Scale score,
Barthel Index score, hypertension, diabetes mellitus, or dyslipidemia data for the participants with is-
chemic stroke
• Inclusion criteria
• Stroke participants, both ischemic and hemorrhagic
• Stroke established by a computed tomographic
• Within 48 hours of onset of the stroke
• Exclusion criteria
• Critically ill patients with other systemic diseases
• People with end-stage renal disease, advanced hepatic disease, psychiatric illness, recurrent
stroke, severe cardiovascular disease associated with arrhythmias
• TIA
Interventions • Experimental group: citicoline plus standard stroke therapy
• Intravenous infusion of citicoline: 1000 mg twice daily during 5 days
• Oral citicoline: 500 mg BID daily for 25 days
• Standard stroke therapy: antihypertensives, osmotic diuretics, lipid-lowering agents, statins, and
if necessary, aspirin or clopidogrel
• Control group (standard stroke therapy)
• Antihypertensives, osmotic diuretics, lipid-lowering agents, statins, and if necessary, aspirin or
clopidogrel
• Duration of treatment: 30 days
• No patient received intravenous thrombolysis
Outcomes • Primary: Barthel Index score
Notes • Identifier trial number: not stated
• Trial conduction dates: January 2014 to January 2015
• A priori sample estimation: no
• Financial disclosures: declared nil financial support
• Other disclosures: did not report any disclosure
• Funding/support: declared nil sponsorship.
Risk of bias
Ghosh 2015 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The selected 100 patients, were randomized ..."
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)
Unclear risk Quote: "The selected 100 patients, were randomized ..."





High risk Quote: "... the authors evaluated the outcome themselves, were not blinded to
the treatment administered and were involved in the management of the pa-
tients."
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Quote: "... the authors evaluated the outcome themselves, were not blinded to








High risk There was no information about either the National Institutes of Health Stroke
Scale or the Barthel Index score baseline, nor adverse events for participants
with ischemic stroke






Methods • Parallel design (2 arms)
• Multicenter study: no
• International: no
• Country: Spain
• Treatment duration: 10 days
• Follow-up period: unknown
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not reported
Participants • CDP-choline: 40
* Control (conventional treatment): 40
* Demographic variables: not stated
• Inclusion criteria
• Either sex
• Over 65 years old
• Acute stage of ischemic stroke as confirmed by computer tomography
• Exclusion criteria: not stated
Interventions • Experimental group: CDP-choline: 1000 mg, intravenously, each 8 hours by 10 days
Guillen 1995 
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• Comparison group: conventional treatment which was not described
• Co-intervention: fluid maintenance therapy and low doses of heparin
Outcomes This issue was not explicitly reported. Trial authors assessed: Glasgow Coma scale, Mathew's scale,
Barthel's scale and the Red Cross scales and tolerability
Notes • Identifier trial number register: not reported
• Trial conduction dates: not reported
• A priori sample estimation: no
• Financial disclosures: not mentioned
• Funding/support: not reported
• Role of the sponsor: not apply
• Data gathered from a conference proceedings
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "... groups arranged at random and a control group ..." (page S76)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)





Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’





Methods • Parallel design (2 arms)
• Multicenter study: yes (59 centers)
• International: yes
• Country: Germany, Portugal, and Spain
• Treatment duration: 6 weeks
• Follow-up period: 6 weeks
• Timing for starting citicoline treatment: first 24 hours after the onset of symptoms
ICTUS 2012 
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• Type of trial (superiority, equivalence or non-inferiority trial): superiority
Participants • Randomized: 2298
• Citicoline (2000 mg): 1148
• Placebo: 1150
• Received medication: 2288
• Citicoline (2000 mg): 1140 (99.3%)
• Placebo: 1148 (99.82%)
• Included into per protocol analysis: 75.48% (1727/2288)
• Citicoline (2000 mg): 50.55% (873/1727)
• Placebo: 49.44% (854/1727)
• Age (mean, years, SD)
• Citicoline (2000 mg): 72.9 (11.8)
• Placebo: 72.8 (12.1)
• Sex (men, %)
• Citicoline (2000 mg): 51.2
• Placebo: 48.2
• Time to treatment (mean, hours)
• Citicoline (2000 mg): ≤ 12 (911 [79.4%]); > 12 (237 [20.6%])
• Placebo: ≤ 12 (916 [79.7%]); > 12 (234 [20.3%])
• Received tissue plasminogen activator (%)
• Citicoline (2000 mg): 532 (46.3)
• Placebo: 532 (46.3)
• Baseline National Institutes of Health Stroke Scale Score (median)
• Citicoline (2000 mg): 15 (IQR: 11 to 19)
• Placebo: 15 (IQR: 11 to 19)
• Hypertension (%)
• Citicoline (2000 mg): 841 (73.3)
• Placebo: 830 (72.2)
• Previous TIA (%)
• Citicoline (2000 mg): 99 (8.6)
• Placebo: 101 (8.8%)
• Previous stroke (%)
• Citicoline (2000 mg): 162 (14.1)
• Placebo: 147 (12.8)
• Cardiac disease (%)
• Citicoline (2000 mg): 200 (17.4)
• Placebo: 188 (16.4)
• Diabetes (%)
• Citicoline (2000 mg): 273 (23.8)
• Placebo: 290 (25.2)
• Inclusion criteria
• Men or women, > 18 years old
• Participants must be treated within 24 hours of their initial stroke symptoms onset
• Participants with a measurable focal neurological deficit lasting for a minimum of 60 minutes
• Participants must have a computerized tomography scan and/or conventional magnetic reso-
nance imaging compatible with the clinical diagnosis of acute ischemic stroke prior to being ran-
domized
• Participants must have an acute ischemic stroke referable to the middle cerebral artery territory
• At inclusion, NIH > 7, with at least 2 of these points from sections 5 & 6 (motor)
• Immediately (i.e. minutes) pre-stroke, modified Rankin score < 2
• Women of childbearing potential must have a negative pregnancy test prior to enrollment
ICTUS 2012  (Continued)
Citicoline for treating people with acute ischemic stroke (Review)









Cochrane Database of Systematic Reviews
• Signed informed consent
• Exclusion criteria
• Participants in coma: participants having a score of 2 or higher in the items regarding the level of
consciousness in the National Institutes of Health Stroke Scale score (1a)
• Computerized tomography scan or conventional magnetic resonance imaging evidence of brain
tumor, cerebral edema with a clinically significant mass midline shi] with compression of the ven-
tricles, brainstem or cerebellar infarction, subarachnoid and/or intracerebral and/or intraventric-
ular hemorrhage
• History of ventricular dysrhythmias, acute myocardial infarction within 72 hours prior to enroll-
ment, unstable angina, decompensated congestive heart failure or any other acute, severe, uncon-
trollable or sustained cardiovascular condition that, in the Investigator's opinion, may interfere
with effective participation in the study
• Previous disorders that may confound the interpretation of the neurological scales
• Drug-addiction-related disorders
• Pre-existing dementia, when dementia implies a disability, measured as a score of 2 or higher in
the previous modified Rankin score
• Pre-existing medical condition that, in the Investigator's opinion, may interfere with the patient's
suitability and participation in the study
• Participants participating in another clinical trial or receiving a non-approved drug (clinical inves-
tigational drug) less than 30 days prior to screening
• Participants under current treatment with citicoline
See Notes
Interventions • Experimental drug: citicoline (CDP-choline, Nicholin, Takeda Chemical Industries, Ltd., Osaka, Japan):
1000 every 12 hours, diluted in a 100 mL saline solution bag and infused during 30 to 60 minutes,
during 3 days and then 1000 mg orally (2 tablets × 500 mg) every 12 hours, until completed 6 weeks
of treatment. In participants with swallowing problems, tablets were dissolved in 30 to 60 mL of tepid
water and administered through a nasogastric tube
• Control: placebo as experimental drug. Control and experimental drug were identical and indistin-
guishable, either ampoules or tablets
• Co-intervention: every participant received stroke care according to local treatment practice, includ-
ing tissue plasminogen activator for eligible patients presenting within 4.5 hours after the onset of
the stroke
Outcomes • Primary: recovery at 90 days as measured by a global test combining the favorable responses from all
3 outcome scales: Barthel index (95 to 100), modified Rankin score (0 to 1), and National Institutes of
Health Stroke Scale Score (0 to 1) assessed at week 12
• Secondary:
• Rate of favorable response in Barthel index
• Rate of favorable response in modified Rankin score
• Rate of favorable response in National Institutes of Health Stroke Scale Score
• The between-groups comparison of the full distribution of the modified Rankin score scores, and
the absolute difference in the National Institutes of Health Stroke Scale Score between baseline
and 3 months
• Death
• Serious adverse events and non-serious adverse events
Note: Quote: "As a post-hoc analysis, and in accordance with reviewers’ recommendations, and
CONSORT guidelines, we updated the previous tabulated meta-analysis for acute ischemic stroke,
which defined success as mRs 0–2."
Notes • This trial was stopped on 21 Octuber 2011 by recommendations from the data and safety monitor-
ing board at the third interim analysis because the statistical stopping boundary for futility had
been crossed. It was based on complete data for 2078 patients, The follow-up was stopped for 220
participants already randomized, but it was suggested that analysis should include all randomized
participants (N = 2298)
ICTUS 2012  (Continued)
Citicoline for treating people with acute ischemic stroke (Review)









Cochrane Database of Systematic Reviews
• Between the second and third interim analyses, there was an amendment of the protocol by rec-
ommendation of the trial steering committee. However the amendment included no changes to
eligibility criteria, clinical outcomes, or statistical analysis
• Identifier trial number: NCT00331890
• Trial conduction dates: 26 November 2006 to 27 Octuber 2011
• A priori sample estimation: yes
• Financial disclosures: yes. Many trial authors had received either consultation fees or honoraria
from sponsor. 1 trial author is a full-time employee of the sponsor
• Funding/support: Ferrer Grupo
• Role of the sponsor: Quote: "The sponsor of the study had no role in study design, data collection,
data analysis, data interpretation, or writing of the report." (page 353). Sponsor supplied citicoline
and placebo
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The randomisation process was centralised using an interactive voice
response system (IVRS), under a minimisation process ..." (Page 350)
There is doubt about the effectiveness of the minimization process to guaran-
tee an appropriate random allocation of the participants
Allocation concealment
(selection bias)
Low risk Quote: "The randomisation process was centralised using an interactive voice
response system (IVRS), under a minimisation process ..." (Page 350)
There is doubt about the effectiveness of the minimization process to guaran-





Low risk Quote: "Patients, researchers, caregivers, individuals assessing the outcomes,
data managers, and members of the trial steering committee were masked to
group assignment." (Page 351)
Control and experimental drug were identical and indistinguishable, either
ampoules or tablets
Blinding of outcome as-
sessment (detection bias)
All outcomes




High risk • Dropouts: 561
• citicoline group: 23.25% (267/1148)
• placebo group: 25.56% (294/1150)
• Included into per protocol analysis: 75.48% (1727/2288)
• Citicoline (2000 mg): 50.55% (873/1727)
• Placebo: 49.44% (854/1727)
Selective reporting (re-
porting bias)
Low risk Trial has information about relevant clinical outcomes, such as described in
the protocol
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Methods • Parallel design: 2 arms
• Multicenter study: no (1 center)
• International: no
• Country: Iran
• Treatment duration: 1 weeks
• Follow-up period: not stated
• Timing for starting citicoline treatment: post 24 hours after the onset of symptoms
• Type of trial (superiority, equivalence or non-inferiority trial): not reported
Participants • Randomized: 64
• Citicoline ( 500 mg): 32
• Placebo: 32
• Age (≥ 40 years-old, %)
• Citicoline (500 mg): 84.37 (27/32)
• Placebo: 93.75 (30/32)
• Sex (men, %)
• Citicoline (500 mg): 78.12 (25/32)
• Placebo: 59.37 (19/32)
• Diabetic
• Citicoline (500 mg): 34.37% (11/32)
• Placebo: 46.87% (15/32)
• Hypertension
• Citicoline (500 mg): 62.5% (20/32)
• Placebo: 59.37(19/32)
• Hyperlipidemia
• Citicoline (500 mg): 28.12% (9/32)
• Placebo: 28.12% (9/32)
• Inclusion criteria
• Participant without history of stroke
• First 24 hours after the onset of symptoms
• Diagnosis confirmed with computerized tomography scan and/or conventional magnetic reso-
nance imaging
• Exclusion criteria
• Embolic or lacunar strokes
• Blood disorders or vasculitis
• Consumer or drugs
Interventions • Experimental: citicoline (500 mg/day), starting on the second day of hospitalization, intravenous dur-
ing 1 week. Additional information about citicoline is unknown
• Comparison: placebo. Additional information about placebo is unknown
• Duration of treatment: 1 week
• Co-intervention: standard treatment, but not stated. Trial authors excluded those participants receiv-
ing recombinant tissue plasminogen activator
Outcomes • Cerebral hemodynamic
• Peak systolic velocity
• Mean flow velocity
• Pulsatility index
• Resistance index.
Notes • Identifier trial number: IRCT 201705278430N9
• Trial conduction dates: just reports the year ‒ 2017
Seifaddini 2017  (Continued)
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• A priori sample estimation: likely yes. Only about power and statistical significance level
• Financial disclosures: not stated
• Funding/support: Neurologic Research Center of Kerman University of Medical Sciences
• Role of the sponsor: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: " ... were divided randomly into two equal groups ..." (Pag 481)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)
Unclear risk It was not reported





Unclear risk Quote "This double-blind ..." (Pag 481)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Blinding of outcome as-
sessment (detection bias)
All outcomes




Unclear risk Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
There is confusion regarding the timing of exclusion of the participants who
received recombinant tissue plasminogen activator
Selective reporting (re-
porting bias)
High risk This trial only reported data about physiological variables
Other bias High risk Design bias
Bias in the presentation of the data. There is confusion regarding the timing of






Methods • Parallel design: 2 arms
• Multicenter study: yes (63 centers)
• International: no
• Country: Japan
• Treatment duration: 2 weeks
• Follow-up period: not stated
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not stated
Participants • Randomized: 272
• Citicoline (1000 mg): 133
Tazaki 1988 
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• Placebo: 139
• Anayzed: 98.16% (267/272)
• Citicoline (1000 mg): 131
• Placebo: 136
• Age (50 to 90 years old)
• Citicoline: 91%
• Placebo: 96.32%
• Sex (men, %)
• Citicoline 66.41 (87/131)
• Placebo: 68.38 (93/136)
• Both: 67.41%
• Inclusion criteria
• Clinical evidence of cerebral infarction occurring within 14 days of admission to the study
• Clinical diagnosis of cerebral infarction confirmed by computed tomography of the brain
• Mild to moderate impairment of consciousness indicated by the Japanese Coma Scale (Appendix
13)
• Exclusion criteria
• Participants with total aphasia, subarachnoid or intracerebral hemorrhage, or indications for neu-
rosurgical intervention
Interventions • Experimental drug: CDP-choline. It was prepared in 20 ml ampoules containing 1000 mg CDP-choline,
diluted with 500 ml physiological saline or 5% dextrose in sterile water and was administered by in-
travenous drip once daily for 14 days
• Control: placebo (physiological saline), in same way as experimental drug
• Co-intervention: no restrictions on the use of concurrent drugs if they were thought to be indicated,
but it should be recorded in detail
Suitable provisions were made so that CDP-choline could not be distinguished from the placebo
Outcomes • The level of consciousness was assessed in 10 grades according to the Japanese Coma Scale
• Global improvement rating
• Global usefulness rating
Notes • Identifier trial number: not stated
• Trial conduction dates: November 1982 to February 1985
• A priori sample estimation: no
• Financial disclosures: not stated
• Funding/support: not stated
• Role of the sponsor: does not apply
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "... randomly assigned to treatment ... or physiological saline (place-
bo) ..." (Page 211)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)




Low risk Quote: " ... central coordinator of the study who was also blinded to the treat-
ment assigned ..." (Page 211)
Tazaki 1988  (Continued)
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All outcomes Quote: "Suitable provisions were made so that CDP-choline could not be dis-
tinguished from the placebo" (Page 211)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Those carrying out the clinical assessments in the study were also




Low risk • Dropouts:1.83% (5/272)




Low risk There was relevant information about the major clinical outcomes and ad-
verse events. However, this trial reported other measures for assessing clinical
effectiveness





Methods • Parallel design (2 arms)
• Multicenter study: no (16 centers)
• International: no
• Country: USA
• Treatment duration: 6 weeks
• Follow-up period: 12 weeks
• Timing for starting citicoline treatment: unclear
• Type of trial (superiority, equivalence or non-inferiority trial): not reported
Participants • Type of participants: acute stroke participants when treated within 24 hours (screened: 2300; random-
ized: 100)
• Citicoline (500 mg): 50
• Placebo: 50
• Analyzed
• Citicoline (500 mg): 41
• Placebo: 40
• Age (year, mean, SE)
• Citicoline (500 mg): 68.5 (1.7)
• Placebo: 72.1 (1.9)
• Sex (men, %)
• Citicoline (500 mg): 56
• Placebo: 47
• Prior stroke or TIA (%)
• Citicoline (500 mg): 49
• Placebo: 35
• Le] hemisphere stroke (%)
• Citicoline (500 mg): 63
• Placebo: 53
• Baseline National Institutes of Health Stroke scale score (mean, SE)
• Citicoline (500 mg): 11.5 (0.7)
• Placebo: 12.7 (0.9)
Warach 2000 
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• Baseline lesion (cc) (mean, SE)
• Citicoline (500 mg): 25.7 (3.4)
• Placebo: 31.9 (5.7)
• Time (hours) stroke to scan (mean, SE)
• Citicoline (500 mg): 13.5 (0.9)
• Placebo: 11.9 (1.0)
• Time (hours) scan to treatment (mean, SE)
• Citicoline (500 mg): 1.6 (0.1)
• Placebo: 1.5 (0.1)
• Time (hours) stroke to treatment (mean, SE)
• Citicoline (500 mg): 15.1 (0.9)
• Placebo: 13.5 (1.0)
• Inclusion criteria
• Age 18 years or older
• Clinical diagnosis of ischemic stroke and symptoms first observed 24 hours or less
• Score on the National Institutes of Health stroke scale score of at least 5 (with at least 2 points due
to motor deficit)$
• An ischemic lesion on the initial diffusion-weighted magnetic resonance imaging involving hemi-
spheric gray matter, specifically the cerebral cortex and/or basal ganglia, of 1 cc or greater and 66
cc or less within the territory of the middle cerebral artery.#
After Clark 1999, the protocol was amended:
$: the minimum National Institutes of Health stroke scale score was raised to 8
#: the maximum lesion volume at enrollment was raised to 120 cc, and the localization was expanded
to include all hemispheric gray matter
• Exclusion criteria
• Participants with a Rankin score greater than or equal to 3 before the index stroke
• Comorbid medical condition compromising study participation or confounding data interpreta-
tion
• Contraindication to magnetic resonance imaging
• Experimental use of thrombolytics
• Previous participation in a prior citicoline study
Interventions • Experimental: citicoline, 1 tablet (500 mg), daily for 6 weeks
• Control: placebo. Additional information was not supplied
• Co-intervention: not reported
Outcomes • Primary
* Change in lesion volume from baseline to week 12
• Secondary
* Quote: "effect of co-variates on lesion change as well as the correlation of imaging results (using
both primary and derived measures) to clinical outcomes (using an improvement on the NIHSS of
seven points or greater)."
Notes • There is no information regarding the impact of the amendment of this protocol
• Identifier trial number: not stated
• Trial conduction dates: not given
• A priori sample estimation: yes. It was not estimated for clinical outcomes
• Financial disclosures: 1 author was a consultant for Interneuron Pharmaceuticals, Lexington, MA, dur-
ing the time Warach 2000 was conducted
• Other disclosures: none
• Funding/support: Interneuron Pharmaceuticals, Lexington, MA
Warach 2000  (Continued)
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• Role of sponsor: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "... 6 weeks after randomization." (Page 715)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Allocation concealment
(selection bias)





Unclear risk Quote: "... double-blind fashion for 6 weeks ..." (Page 715)
Insufficient information to permit judgment of ‘low risk’ or ‘high risk’
Trial authors provided no information regarding how to guarantee appropriate
blinding
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Quote: "Those performing image reading and quantification were blinded to




High risk • Dropouts: 19% (19/100)
• Citicoline (500 mg): 18% (9/50)
• Placebo: 20% (10/50)
Selective reporting (re-
porting bias)
Low risk There was information regarding death, NIH Stroke Scale score and adverse
events
Other bias High risk Measurements and confounding biases: there is no information regarding the






TIA: transient ischemic attack
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Dereux 1987 RCT; reported no clinical diagnosis with imaging
Djoenady 1981 RCT; reported no clinical diagnosis with imaging
ECCS- AIS 2012 RCT; reported no clinical diagnosis with imaging
Garcia Pastor 2004 RCT; reported no clinical diagnosis with imaging
Goas 1980 RCT; reported no clinical diagnosis with imaging
Melnikova 2011 RCT; reported no clinical diagnosis with imaging
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Study Reason for exclusion
Panteleienko 2009 RCT; reported no clinical diagnosis with imaging
RCT: randomized controlled trial
 









Characteristics of ongoing studies [ordered by study ID]
 
Study name Citicoline in acute ischemic stroke - a randomized control trial
Methods • Randomized
• 2 arms
Participants • Acute ischemic stroke
• Age > 18 years
• Satisfying criteria for reperfusion therapy (thrombolysis or thrombectomy)
Interventions • Citicoline arm: 1 gm intravenous therapy for 3 days followed by oral treatment (1000 mg twice
daily) for 39 days
• Placebo arm: no more information
Outcomes • Primary outcome is change in stroke volume from baseline to week 6
• Secondary outcomes are mRS 0–2, NIHSS 0–2, Barthel Index more than or equal to 95 and mor-
tality at 90 days
Starting date Not reported
Contact information A Agarwal
All India Institute of Medical Sciences, Neurology, New Delhi
Notes Estimated sample size: 116 participants in 2 years
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Study name • Scientific title: Effect of citicoline versus placebo on clinical signs in patients with acute ischemic
and hemorrhagic stroke: a triple blind control trial
• Public title: Effect of citicoline versus placebo on clinical signs in patients with acute ischemic and
hemorrhagic stroke
Methods • Purpose: treatment
• Parallel-design
• Randomized
• Binding: triple blind control trial
• Phase: 2
• Sample size (target sample size): 160
Participants • Age: between 18 years-old and 85 years old
• Sex: both
• Inclusion criteria
• Age of 18 to 85 years
• Acute stroke
• NIHSS score between 6 to 22
• Exclusion criteria:
• History of stroke
• Renal or liver disorder
• Neoplasia
• Active infectious disease during last month
• Trauma or surgery during last month
• History of collagen vascular disease
• Immunosuppressive medications or corticosteroid
• Signs of brain hernia
• Convulsion at the time of stroke
• Neurologic disease or dementia
• Pregnancy or breastfeeding
• Receiving vasodilator medications
Interventions • Experimental group: infusion of citicoline 1 gr in normal saline (overall 20 mL) once daily for 10
days
• Control group: infusion of 20 mL normal saline once daily for 10 days
Outcomes • Primary outcomes (at baseline and 10 and 90 days after intervention)
• National Institutes of Health Stroke Scale
• Barthel Index
• Modified Rankin Scale
• Secondary outcomes: not stated
Starting date Expected recruitment start date: 20 February 2016
Expected recruitment end date: 18 February 2017
Contact information Dr Shahir Mazaheri, Sina Hospital, Mirzadeh Eshghi Ave. Hamadan, Iran (Islamic Republic of)
E-mail: sh.mazaheri@umsha.ac.ir
Phone: +98 81 3827 4184
IRCT201601289014N90 
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Notes Sponsors/Funding sources: Vice-chancellor for Research the Technology, Hamadan University of
Medical Sciences, Dr Saeid Bashirian, Hamadan, University of Medical Scienc1868e165s, Shahid





D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Citicoline versus placebo or not intervention
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 All-cause mortality 8 4362 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.83, 1.07]
1.1.1 Citicoline 500 mg/day 2 494 Risk Ratio (M-H, Fixed,
95% CI)
1.07 [0.70, 1.62]
1.1.2 Citicoline 1000 mg/day 1 272 Risk Ratio (M-H, Fixed,
95% CI)
0.57 [0.22, 1.50]
1.1.3 Citicoline 500, 1000 or 2000 mg/day 1 259 Risk Ratio (M-H, Fixed,
95% CI)
1.01 [0.52, 1.94]
1.1.4 Citicoline 2000 mg/day 4 3337 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.81, 1.08]
1.2 All-cause mortality: subgroup analysis 8 4362 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.83, 1.07]
1.2.1 Trials without support by pharma-
ceutical companies
2 335 Risk Ratio (M-H, Fixed,
95% CI)
0.78 [0.41, 1.49]
1.2.2 Trials supported by pharmaceutical
companies
6 4027 Risk Ratio (M-H, Fixed,
95% CI)
0.95 [0.83, 1.08]
1.3 All-cause mortality: subgroup analysis 8 4362 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.83, 1.07]
1.3.1 Trials with ≤ 200 participants 3 240 Risk Ratio (M-H, Fixed,
95% CI)
1.26 [0.70, 2.29]
1.3.2 Trials with > 200 participants 5 4122 Risk Ratio (M-H, Fixed,
95% CI)
0.93 [0.81, 1.06]
1.4 All-cause mortality: sensitivity analy-
sis: impact of missing outcome data
8 4362 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.83, 1.07]
1.4.1 Trials non-reporting missing data 4 1615 Risk Ratio (M-H, Fixed,
95% CI)
0.99 [0.79, 1.23]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.4.2 Trials reporting missing data 4 2747 Risk Ratio (M-H, Fixed,
95% CI)
0.92 [0.78, 1.07]
1.5 All-cause mortality: sensitivity analy-
sis: best-case scenario
8   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.5.1 Trials without missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
0.99 [0.80, 1.24]
1.5.2 Trial with missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
0.42 [0.37, 0.49]
1.6 All-cause mortality: sensitivity analy-
sis: worst-case scenario
8   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.6.1 Trials without missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
0.99 [0.79, 1.23]
1.6.2 Trial with missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
2.04 [1.79, 2.33]
1.7 All-cause mortality: sensitivity analy-
sis: the Gamble-Hollis analysis
8   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.7.1 Trials without missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
0.99 [0.79, 1.23]
1.7.2 Trial with missing data 4   Risk Ratio (IV, Fixed, 95%
CI)
0.86 [0.45, 1.64]
1.8 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale)
4 3668 Risk Ratio (M-H, Fixed,
95% CI)
1.11 [0.97, 1.26]
1.9 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale): subgroup analysis
4 3668 Risk Ratio (M-H, Fixed,
95% CI)
1.11 [0.97, 1.26]
1.9.1 Trials with ≤ 200 participants 1 77 Risk Ratio (M-H, Fixed,
95% CI)
1.33 [0.67, 2.67]
1.9.2 Trials with > 200 participants 3 3591 Risk Ratio (M-H, Fixed,
95% CI)
1.10 [0.96, 1.25]
1.10 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale): sensitivity analysis: impact of
missing outcome data
4   Risk Ratio (M-H, Fixed,
95% CI)
Subtotals only
1.10.1 Trials without missing data 2 1293 Risk Ratio (M-H, Fixed,
95% CI)
1.23 [1.01, 1.50]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.10.2 Trials with missing data 2 2375 Risk Ratio (M-H, Fixed,
95% CI)
1.03 [0.87, 1.22]
1.11 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale): sensitivity analysis: best-case sce-
nario
4   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.11.1 Trial without missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
1.23 [1.00, 1.50]
1.11.2 Trial with missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
0.44 [0.39, 0.51]
1.12 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale): sensitivity analysis: worst-case
scenario
4   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.12.1 Trial without missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
1.23 [1.00, 1.50]
1.12.2 Trial with missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
2.33 [2.03, 2.69]
1.13 Patients with moderate or lower de-
gree of disability or dependence (accord-
ing to < 3 scores in the modified Rankin
scale): sensitivity analysis: the Gam-
ble-Hollis analysis
4   Risk Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.13.1 Trial without missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
1.23 [1.00, 1.50]
1.13.2 Trial with missing data 2   Risk Ratio (IV, Fixed, 95%
CI)
1.14 [0.54, 2.42]
1.14 Severe adverse events 5   Risk Ratio (M-H, Fixed,
95% CI)
Subtotals only
1.14.1 Cardiovascular 3 3591 Risk Ratio (M-H, Fixed,
95% CI)
1.04 [0.84, 1.29]
1.14.2 Central nervous system (including
hemorrhagic or ischemic stroke)
3 3591 Risk Ratio (M-H, Fixed,
95% CI)
1.30 [1.07, 1.59]
1.14.3 Respiratory (including pneumonia) 3 3591 Risk Ratio (M-H, Fixed,
95% CI)
1.01 [0.78, 1.31]
1.14.4 Gastrointestinal 3 1370 Risk Ratio (M-H, Fixed,
95% CI)
0.64 [0.40, 1.00]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.14.5 Musculoskeletal 2 1293 Risk Ratio (M-H, Fixed,
95% CI)
1.52 [0.50, 4.60]
1.14.6 Hepatic dysfunction 1 267 Risk Ratio (M-H, Fixed,
95% CI)
0.78 [0.18, 3.41]
1.14.7 Renal and urologic disorders 3 1560 Risk Ratio (M-H, Fixed,
95% CI)
2.04 [0.99, 4.22]
1.14.8 Hematological disorders 3 1560 Risk Ratio (M-H, Fixed,
95% CI)
1.27 [0.46, 3.51]
1.15 Non-severe adverse events 1   Risk Ratio (M-H, Fixed,
95% CI)
Subtotals only
1.15.1 Cardiac disorders 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
0.94 [0.82, 1.08]
1.15.2 Pyrexia 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
1.02 [0.87, 1.19]
1.15.3 Constipation 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
1.03 [0.88, 1.20]
1.15.4 Urinary tract infections 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
1.06 [0.89, 1.26]
1.15.5 Headache 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
0.96 [0.79, 1.18]
1.15.6 Nausea and vomiting symptoms 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
0.95 [0.77, 1.16]





1 2298 Risk Ratio (M-H, Fixed,
95% CI)
0.98 [0.74, 1.29]
1.15.9 Pneumonia 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
1.02 [0.73, 1.41]
1.15.10 Hypotension 1 2298 Risk Ratio (M-H, Fixed,
95% CI)
0.92 [0.63, 1.36]
1.16 Functional recovery: assessed with
the Barthel Index
6   Risk Ratio (M-H, Fixed,
95% CI)
Subtotals only
1.16.1 50 points 1 77 Risk Ratio (M-H, Fixed,
95% CI)
1.26 [0.71, 2.26]
1.16.2 ≥ 95 points 4 3850 Risk Ratio (M-H, Fixed,
95% CI)
1.03 [0.94, 1.13]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.16.3 85 to 100 points 1 63 Risk Ratio (M-H, Fixed,
95% CI)
3.12 [1.10, 8.91]
1.17 Patients with minor impairment (ac-
cording to ≤ 1 scores in the National Insti-
tutes of Health Stroke Scale)





Analysis 1.1.   Comparison 1: Citicoline versus placebo or not intervention, Outcome 1: All-cause mortality
Study or Subgroup





Heterogeneity: Chi² = 1.73, df = 1 (P = 0.19); I² = 42%
Test for overall effect: Z = 0.30 (P = 0.77)





Test for overall effect: Z = 1.14 (P = 0.25)





Test for overall effect: Z = 0.02 (P = 0.99)







Heterogeneity: Chi² = 0.42, df = 3 (P = 0.94); I² = 0%
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.46, df = 7 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)










































































M-H, Fixed, 95% CI
0.93 [0.59 , 1.47]
2.08 [0.68 , 6.31]
1.07 [0.70 , 1.62]
0.57 [0.22 , 1.50]
0.57 [0.22 , 1.50]
1.01 [0.52 , 1.94]
1.01 [0.52 , 1.94]
0.82 [0.24 , 2.83]
1.00 [0.75 , 1.33]
1.09 [0.45 , 2.65]
0.91 [0.78 , 1.08]
0.94 [0.81 , 1.08]
0.94 [0.83 , 1.07]
Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours citicoline Favours placebo or not intervention
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Analysis 1.2.   Comparison 1: Citicoline versus placebo or not
intervention, Outcome 2: All-cause mortality: subgroup analysis
Study or Subgroup





Heterogeneity: Chi² = 0.97, df = 1 (P = 0.33); I² = 0%
Test for overall effect: Z = 0.76 (P = 0.45)









Heterogeneity: Chi² = 2.31, df = 5 (P = 0.81); I² = 0%
Test for overall effect: Z = 0.79 (P = 0.43)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.46, df = 7 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
































































M-H, Fixed, 95% CI
1.09 [0.45 , 2.65]
0.57 [0.22 , 1.50]
0.78 [0.41 , 1.49]
0.82 [0.24 , 2.83]
1.01 [0.52 , 1.94]
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
0.91 [0.78 , 1.08]
2.08 [0.68 , 6.31]
0.95 [0.83 , 1.08]
0.94 [0.83 , 1.07]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours citicoline Favours placebo
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Analysis 1.3.   Comparison 1: Citicoline versus placebo or not
intervention, Outcome 3: All-cause mortality: subgroup analysis
Study or Subgroup






Heterogeneity: Chi² = 1.34, df = 2 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.77 (P = 0.44)








Heterogeneity: Chi² = 1.30, df = 4 (P = 0.86); I² = 0%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.46, df = 7 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
































































M-H, Fixed, 95% CI
0.82 [0.24 , 2.83]
1.09 [0.45 , 2.65]
2.08 [0.68 , 6.31]
1.26 [0.70 , 2.29]
1.01 [0.52 , 1.94]
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
0.91 [0.78 , 1.08]
0.57 [0.22 , 1.50]
0.93 [0.81 , 1.06]
0.94 [0.83 , 1.07]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours citicoline Favours placebo
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Analysis 1.4.   Comparison 1: Citicoline versus placebo or not intervention, Outcome
4: All-cause mortality: sensitivity analysis: impact of missing outcome data
Study or Subgroup







Heterogeneity: Chi² = 0.12, df = 3 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.91)







Heterogeneity: Chi² = 3.04, df = 3 (P = 0.38); I² = 1%
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.46, df = 7 (P = 0.84); I² = 0%
Test for overall effect: Z = 0.93 (P = 0.35)
































































M-H, Fixed, 95% CI
1.01 [0.52 , 1.94]
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
1.09 [0.45 , 2.65]
0.99 [0.79 , 1.23]
0.82 [0.24 , 2.83]
0.91 [0.78 , 1.08]
0.57 [0.22 , 1.50]
2.08 [0.68 , 6.31]
0.92 [0.78 , 1.07]
0.94 [0.83 , 1.07]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours citicoline Favours placebo
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Analysis 1.5.   Comparison 1: Citicoline versus placebo or not intervention,
Outcome 5: All-cause mortality: sensitivity analysis: best-case scenario
Study or Subgroup






Heterogeneity: Chi² = 0.15, df = 3 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.06 (P = 0.95)






Heterogeneity: Chi² = 1.31, df = 3 (P = 0.73); I² = 0%
Test for overall effect: Z = 12.51 (P < 0.00001)































IV, Fixed, 95% CI
1.05 [0.54 , 2.03]
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
1.09 [0.45 , 2.65]
0.99 [0.80 , 1.24]
0.31 [0.11 , 0.86]
0.42 [0.37 , 0.48]
0.45 [0.18 , 1.14]
0.61 [0.29 , 1.30]
0.42 [0.37 , 0.49]
Risk Ratio
IV, Fixed, 95% CI
0.2 0.5 1 2 5
Favours citicoline Favours control
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Analysis 1.6.   Comparison 1: Citicoline versus placebo or not intervention,
Outcome 6: All-cause mortality: sensitivity analysis: worst-case scenario
Study or Subgroup






Heterogeneity: Chi² = 0.12, df = 3 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.10 (P = 0.92)






Heterogeneity: Chi² = 6.89, df = 3 (P = 0.08); I² = 56%
Test for overall effect: Z = 10.66 (P < 0.00001)































IV, Fixed, 95% CI
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
1.01 [0.52 , 1.94]
1.09 [0.45 , 2.65]
0.99 [0.79 , 1.23]
0.76 [0.32 , 1.84]
2.06 [1.80 , 2.36]
2.35 [0.88 , 6.23]
4.28 [1.54 , 11.88]
2.04 [1.79 , 2.33]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours citicoline Favours control
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Analysis 1.7.   Comparison 1: Citicoline versus placebo or not intervention,
Outcome 7: All-cause mortality: sensitivity analysis: the Gamble-Hollis analysis
Study or Subgroup






Heterogeneity: Chi² = 0.12, df = 3 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.10 (P = 0.92)






Heterogeneity: Chi² = 1.36, df = 3 (P = 0.72); I² = 0%
Test for overall effect: Z = 0.44 (P = 0.66)































IV, Fixed, 95% CI
1.01 [0.52 , 1.94]
0.93 [0.59 , 1.47]
1.00 [0.75 , 1.33]
1.09 [0.45 , 2.65]
0.99 [0.79 , 1.23]
0.82 [0.11 , 6.23]
0.91 [0.36 , 2.32]
0.57 [0.18 , 1.83]
2.08 [0.32 , 13.37]
0.86 [0.45 , 1.64]
Risk Ratio
IV, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours citicoline Favours control
 
 
Analysis 1.8.   Comparison 1: Citicoline versus placebo or not intervention, Outcome 8: Patients with








Heterogeneity: Chi² = 3.03, df = 3 (P = 0.39); I² = 1%
Test for overall effect: Z = 1.53 (P = 0.13)


































M-H, Fixed, 95% CI
1.33 [0.67 , 2.67]
1.07 [0.75 , 1.53]
1.31 [1.02 , 1.66]
1.02 [0.85 , 1.21]
1.11 [0.97 , 1.26]
Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours placebo Favours citicoline
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Analysis 1.9.   Comparison 1: Citicoline versus placebo or not intervention, Outcome 9: Patients with moderate or
lower degree of disability or dependence (according to < 3 scores in the modified Rankin scale): subgroup analysis
Study or Subgroup





Test for overall effect: Z = 0.82 (P = 0.41)






Heterogeneity: Chi² = 2.75, df = 2 (P = 0.25); I² = 27%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 3.03, df = 3 (P = 0.39); I² = 1%
Test for overall effect: Z = 1.53 (P = 0.13)












































M-H, Fixed, 95% CI
1.33 [0.67 , 2.67]
1.33 [0.67 , 2.67]
1.07 [0.75 , 1.53]
1.31 [1.02 , 1.66]
1.02 [0.85 , 1.21]
1.10 [0.96 , 1.25]
1.11 [0.97 , 1.26]
Risk Ratio
M-H, Fixed, 95% CI
0.5 0.7 1 1.5 2
Favours placebo Favours citicoline
 
 
Analysis 1.10.   Comparison 1: Citicoline versus placebo or not intervention, Outcome
10: Patients with moderate or lower degree of disability or dependence (according to < 3
scores in the modified Rankin scale): sensitivity analysis: impact of missing outcome data
Study or Subgroup





Heterogeneity: Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 2.01 (P = 0.04)





Heterogeneity: Chi² = 0.56, df = 1 (P = 0.45); I² = 0%
Test for overall effect: Z = 0.35 (P = 0.73)







































M-H, Fixed, 95% CI
1.07 [0.75 , 1.53]
1.31 [1.02 , 1.66]
1.23 [1.01 , 1.50]
1.33 [0.67 , 2.67]
1.02 [0.85 , 1.21]
1.03 [0.87 , 1.22]
Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours placebo Favours citicoline
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Analysis 1.11.   Comparison 1: Citicoline versus placebo or not intervention, Outcome
11: Patients with moderate or lower degree of disability or dependence (according
to < 3 scores in the modified Rankin scale): sensitivity analysis: best-case scenario
Study or Subgroup




Heterogeneity: Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 2.00 (P = 0.05)




Heterogeneity: Chi² = 3.07, df = 1 (P = 0.08); I² = 67%
Test for overall effect: Z = 11.51 (P < 0.00001)



















IV, Fixed, 95% CI
1.07 [0.75 , 1.53]
1.30 [1.03 , 1.66]
1.23 [1.00 , 1.50]
0.73 [0.41 , 1.30]
0.43 [0.37 , 0.50]
0.44 [0.39 , 0.51]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours control Favours citicoline
 
 
Analysis 1.12.   Comparison 1: Citicoline versus placebo or not intervention, Outcome
12: Patients with moderate or lower degree of disability or dependence (according
to < 3 scores in the modified Rankin scale): sensitivity analysis: worst-case scenario
Study or Subgroup




Heterogeneity: Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 2.00 (P = 0.05)




Heterogeneity: Chi² = 0.08, df = 1 (P = 0.78); I² = 0%
Test for overall effect: Z = 11.74 (P < 0.00001)



















IV, Fixed, 95% CI
1.07 [0.75 , 1.53]
1.30 [1.03 , 1.66]
1.23 [1.00 , 1.50]
2.13 [1.12 , 4.05]
2.34 [2.03 , 2.71]
2.33 [2.03 , 2.69]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours control Favours citicoline
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Analysis 1.13.   Comparison 1: Citicoline versus placebo or not intervention, Outcome
13: Patients with moderate or lower degree of disability or dependence (according to <
3 scores in the modified Rankin scale): sensitivity analysis: the Gamble-Hollis analysis
Study or Subgroup




Heterogeneity: Chi² = 0.81, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 2.00 (P = 0.05)




Heterogeneity: Chi² = 0.13, df = 1 (P = 0.72); I² = 0%
Test for overall effect: Z = 0.35 (P = 0.72)



















IV, Fixed, 95% CI
1.07 [0.75 , 1.53]
1.30 [1.03 , 1.66]
1.23 [1.00 , 1.50]
1.34 [0.43 , 4.21]
1.02 [0.38 , 2.74]
1.14 [0.54 , 2.42]
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours control Favours citicoline
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Heterogeneity: Chi² = 1.02, df = 2 (P = 0.60); I² = 0%
Test for overall effect: Z = 0.38 (P = 0.70)






Heterogeneity: Chi² = 27.31, df = 2 (P < 0.00001); I² = 93%
Test for overall effect: Z = 2.66 (P = 0.008)






Heterogeneity: Chi² = 0.13, df = 2 (P = 0.94); I² = 0%







Heterogeneity: Chi² = 6.55, df = 2 (P = 0.04); I² = 69%






Heterogeneity: Chi² = 0.27, df = 1 (P = 0.60); I² = 0%
























































































































M-H, Fixed, 95% CI
0.85 [0.54 , 1.34]
1.07 [0.80 , 1.43]
1.16 [0.76 , 1.76]
1.04 [0.84 , 1.29]
3.91 [2.34 , 6.53]
0.85 [0.65 , 1.12]
1.14 [0.79 , 1.64]
1.30 [1.07 , 1.59]
1.11 [0.63 , 1.96]
0.98 [0.69 , 1.40]
1.00 [0.61 , 1.64]
1.01 [0.78 , 1.31]
3.08 [0.13 , 73.26]
0.31 [0.15 , 0.64]
0.98 [0.52 , 1.87]
0.64 [0.40 , 1.00]
2.38 [0.28 , 20.15]
1.23 [0.33 , 4.55]
1.52 [0.50 , 4.60]
0.78 [0.18 , 3.41]
0.78 [0.18 , 3.41]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 1.14.   (Continued)
Test for overall effect: Z = 0.33 (P = 0.74)






Heterogeneity: Chi² = 1.85, df = 2 (P = 0.40); I² = 0%







Heterogeneity: Chi² = 0.97, df = 2 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)









































6.18 [0.82 , 46.75]
1.53 [0.67 , 3.50]
1.04 [0.07 , 16.43]
2.04 [0.99 , 4.22]
2.38 [0.28 , 20.15]
1.23 [0.33 , 4.55]
0.35 [0.01 , 8.42]
1.27 [0.46 , 3.51]
0.001 0.1 1 10 1000
Favours citcoline Favours control
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Test for overall effect: Z = 0.33 (P = 0.74)











Test for overall effect: Z = 0.35 (P = 0.73)











Test for overall effect: Z = 1.47 (P = 0.14)





















































































M-H, Fixed, 95% CI
0.94 [0.82 , 1.08]
0.94 [0.82 , 1.08]
1.02 [0.87 , 1.19]
1.02 [0.87 , 1.19]
1.03 [0.88 , 1.20]
1.03 [0.88 , 1.20]
1.06 [0.89 , 1.26]
1.06 [0.89 , 1.26]
0.96 [0.79 , 1.18]
0.96 [0.79 , 1.18]
0.95 [0.77 , 1.16]
0.95 [0.77 , 1.16]
1.20 [0.94 , 1.54]
1.20 [0.94 , 1.54]
0.98 [0.74 , 1.29]
Risk Ratio
M-H, Fixed, 95% CI
 
 
Citicoline for treating people with acute ischemic stroke (Review)









Cochrane Database of Systematic Reviews
Analysis 1.15.   (Continued)

















Test for overall effect: Z = 0.40 (P = 0.69)































0.98 [0.74 , 1.29]
0.98 [0.74 , 1.29]
1.02 [0.73 , 1.41]
1.02 [0.73 , 1.41]
0.92 [0.63 , 1.36]
0.92 [0.63 , 1.36]
0.01 0.1 1 10 100
Favours citicoline Favours control
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Analysis 1.16.   Comparison 1: Citicoline versus placebo or not intervention,







Test for overall effect: Z = 0.79 (P = 0.43)







Heterogeneity: Chi² = 3.92, df = 3 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.64 (P = 0.53)





Test for overall effect: Z = 2.13 (P = 0.03)






















































M-H, Fixed, 95% CI
1.26 [0.71 , 2.26]
1.26 [0.71 , 2.26]
1.29 [0.88 , 1.91]
1.00 [0.77 , 1.29]
1.14 [0.96 , 1.35]
0.96 [0.84 , 1.09]
1.03 [0.94 , 1.13]
3.13 [1.10 , 8.91]
3.13 [1.10 , 8.91]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours placebo Favours citicoline
 
 
Analysis 1.17.   Comparison 1: Citicoline versus placebo or not intervention, Outcome 17: Patients









Heterogeneity: Chi² = 5.50, df = 4 (P = 0.24); I² = 27%
Test for overall effect: Z = 1.31 (P = 0.19)







































M-H, Fixed, 95% CI
1.57 [0.85 , 2.93]
1.10 [0.77 , 1.59]
1.25 [0.98 , 1.60]
1.02 [0.88 , 1.18]
0.76 [0.47 , 1.23]
1.08 [0.96 , 1.21]
Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours citicoline
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Outcome Fixed-effect Random-effects
All-cause mortality RR 0.94, 95% CI 0.83 to 1.07; I2 =
0%
RR 0.94, 95% CI 0.83 to 1.07; I2 =
0%
Degree of disability or dependence in daily activities ac-
cording to the modified Rankin scale
RR 1.11, 95% CI 0.97 to 1.26; I2 =
1%
RR 1.11, 95% CI 0.97 to 1.26; I2 =
1%
Severe adverse events (Reporting cardiovascular adverse
events)
RR 1.04 95% CI 0.84 to 1.29; I2 =
0%
RR 1.04 95% CI 0.84 to 1.28; I2 =
0%
Functional recovery: assessed with the Barthel Index (≥95
points)
RR 1.03, 95% CI 0.94 to 1.13; I2 =
24%
RR 1.05, 95% CI 0.93 to 1.17; I2 =
24%
Neurological function assessed with the National Institutes
of Health Stroke Scale (NIHSS):≤1 points)
RR 1.08, 95% CI 0.96 to 1.21; I2 =
27%
RR 1.09, 95% CI 0.93 to 1.27; I2 =
27%




Alviarez 2007 Quote: "A patient in the active group with a history of gastric ulcer presented a digestive bleeding
and the treatment was discontinued; no adverse effects were reported in the placebo group."
Warach 2000 Quote: "Only two adverse events were seen seen in greater incidence in the citicoline group: edema
of the extremities ( p ≤ 0.05) and back pain (p ≤ 0.10)."
Ghosh 2015 Not reported
Guillen 1995 Quote: "In addition it was tolerated very well."
ICTUS 2012 Appropriate report (Analysis 1.14)
Seifaddini 2017 Not reported
Tazaki 1988 See Analysis 1.14 for severe adverse events
Quote: "No serious adverse effects were related to treatment with CDP-choline in any patient with
cerebral infarction."
Clark 1997 Quote: "There were no serious adverse events reasonably attributed to the study medication. The
only adverse events that were significantly different between the treatment groups and placebo
group were dizziness and accidental injury, primarily related to falling. Of the patients who fell, on-
ly one (2000 mg group) was of clinical significance (associated with hip fracture), whereas the re-
mainder were minor in nature. It should be noted that the patients who were experiencing dizzi-
ness were not the same patients who experienced accidental injuries."
Clark 1999 Appropriate report (Analysis 1.14)
Clark 2001 Appropriate report (Analysis 1.14)
Table 2.   Included trials: description of the harms 
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No/77 4/2 Not stated NA NA NA NA Quote: "The Citicholine was superior to place-
bo to improve the percentage of patients that
can be assisted to if same after an episode of
ictus acute, taken place by the occlusion of








Yes No 80% Not re-
ported
Not stated Quote: "We found a significant inverse rela-
tionship between lesion volume change over
12 weeks as measured by MRI and clinical
outcome for ischemic stroke. This relation-
ship supports the role of DWI as a surrogate
marker of clinically meaningful lesion pro-
gression in stroke clinical trials. The hypothe-
sis that citicoline reduces lesion growth and
















No/100 1/2 Yes Yes NA NA NA Quote: "Treatment with citicoline in patients
of stroke, presenting within 48 h of onset, in-
creases the probability of recovery and a fa-
vorable outcome at the end of the 1st and the
3rd month in all stroke groups. A large ran-
domized control trial is necessary in near fu-




No/40 5/2 No stated NA NA NA NA Quote: "CDP-choline seemed better than the
placebo, leading to improvement as quan-
tified by the GCS (p<.05), Mathew's Scale





Yes/2298 7/2 Yes Yes Yes Yes Yes Quote: "Under the circumstances of the IC-
TUS trial, citicoline is not efficacious in the
-









































































































































4/2 Yes No Yes Yes Not stated Quote: "Prescription of citicoline for treat-
ment of acute ischemic stroke is associated
with hemodynamic changes in cerebral ar-
teries. This finding can be one of the citicol-





No/272 3/2 No NA NA NA NA Quote: "The group treated with CDP-choline
showed significant improvements in level
of consciousness compared with the place-
bo-treated group, and CDP-choline was an
entirely safe treatment."
-
Clark 1997 No/259 6/4 Yes Yes NA NA NA Quote: "This study suggests that oral citico-
line can be used safely with minimal side ef-
fects in acute stroke treatment. Citicoline ap-
pears to improve functional outcome and re-
duce neurologic deficit with 500 mg of citicol-
ine appearing to be the optimal dose."
-
Clark 1999 Yes/394 9/2 Yes Yes Yes Yes Yes Quote: "The results of this study indicate that
citicoline was safe but ineffective in improv-
ing the outcome of patients with acute is-
chemic stroke who were enrolled in this trial."
-
Clark 2001 Yes/899 9/2 Yes Yes Yes Yes Yes Quote: "Citicoline was safe but ineffective in
improving the outcome of patients with acute
ischemic stroke as measured by the planned
analyses."
-
Table 3.   Sample size estimation a priori and trial's conclusions  (Continued)
DWI: diQusion-weighted magnetic resonance imaging
GCS: Glasgow Coma scale.
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A P P E N D I C E S
Appendix 1. Modified Rankin scale for neurologic disability
 
Domain Grade
No symptoms at all 0
No significant disability despite symptoms: able to carry out all usual duties and activities 1
Slight disability: unable to carry out all previous activities but able to look after own affairs without
assistance
2
Moderate disability: requiring some help, but able to walk without assistance 3
Moderately severe disability: unable to walk without assistance, and unable to attend to own bodi-
ly needs without assistance
4
Severe disability: bedridden, incontinent, and requiring constant nursing care and attention 5
Dead (this outcome was added for clinical trial purposes and was not part of the original scale) 6
Source: van Swieten 1988; Harrison 2013
 
 
Appendix 2. The Barthel Index
 
The Barthel Index
  With Help Independent
Feeding (if food needs to be cut up = help) 5 10
Moving from wheelchair to bed and return (includes sitting up in bed) 5-10 15
Personal toilet (wash face, comb hair, shave, clean teeth) 0 5
Getting on and oQ toilet (handling clothes, wipe, flush) 5 10
Bathing self 0 5
Walking on level surface (or if unable to walk, propel wheelchair) 10 15
Propelling a wheelchair (*score only if unable to walk) 0 5
Ascend and descend stairs 5 10
Dressing (includes tying shoes, fastening fasteners) 5 10
Controlling bowels 5 10
Controlling bladder 5 10
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A patient scoring 100 BI is continent, feeds himself, dresses himself, gets up out of bed and chairs, bathes himself, walks at least a
block, and can ascend and descend stairs. This does not mean that he is able to live alone: he may not be able to cook, keep house,
and meet the public, but he is able to get along without attendant care
Definition and discussion of scoring
• Feeding
10 = Independent. The patient can feed himself a meal from a tray or table when someone puts the food within his reach. He must put
on an assistive device if this is needed, cut up the food, use salt and pepper, spread butter, etc. He must accomplish this in a reason-
able time.
5 = Some help is necessary (with cutting up food, etc., as listed above).
 
• Moving from wheelchair to bed and return
15 = Independent in all phases of this activity. Patient can safely approach the bed in his wheelchair, lock brakes, li] footrests, move
safely to bed, lie down, come to a sitting position on the side of the bed, change the position of the wheelchair, if necessary, to trans-
fer back into it safely, and return to the wheelchair.
10 = Either some minimal help is needed in some step of this activity or the patient needs to be reminded or supervised for safety of
one or more parts of this activity.
5 = Patient can come to a sitting position without the help of a second person but needs to be lifted out of bed, or, if he transfers, re-
quires a great deal of help.
 
• Doing personal toilet
5 = Patient can wash hands and face, comb hair, clean teeth, and shave. He may use any kind of razor but must put in blade or plug in
razor without help, as well as get it from drawer or cabinet. Female patients must put on own makeup, if used, but need not braid or
style hair.
 
• Getting on and o= toilet
10 = Patient is able to get on and oQ toilet, fasten and unfasten clothes, prevent soiling of clothes, and use toilet paper without help.
He may use a wall bar or other stable object for support if needed. If it is necessary to use a bed pan instead of a toilet, he must be
able to place it on a chair, empty it, and clean it.
5 = Patient needs help because of imbalance or in handling clothes or in using toilet paper.
 
• Bathing self
5 = Patient may use a bath tub, a shower, or take a complete sponge bath. He must be able to do all the steps involved in whichever
method is employed without another person being present.
 
• Walking on a level surface
15 = Patient can walk at least 50 yards without help or supervision. He may wear braces or prostheses and use crutches, canes, or a
walkerette but not a rolling walker. He must be able to lock and unlock braces if used, assume the standing position and sit down, get
the necessary mechanical aides into position for use, and dispose of them when he sits. (Putting on and taking oQ braces is scored
under dressing.)
  (Continued)
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10 = Patient needs help or supervision in any of the above but can walk at least 50 yards with a little help.
 
• Propelling a wheelchair
5 = If a patient cannot ambulate but can propel a wheelchair independently. He must be able to go around corners, turn around, ma-
neuver the chair to a table, bed, toilet, etc. He must be able to push a chair at least 50 yards. Do not score this item if the patient gets
score for walking.
 
• Ascending and descending stairs
10 = Patient is able to go up and down a flight of stairs safely without help or supervision. He may, and should, use handrails, canes,
or crutches when needed. He must be able to carry canes or crutches as he ascends or descends stairs.
5 = Patient needs help with or supervision of any one of the above items.
 
• Dressing and undressing
10 = Patient is able to put on, remove and fasten all clothing, and tie shoe laces (unless it is necessary to use adaptations for this).
The activity includes putting on and removing and fastening corset or braces when these are prescribed. Such special clothing as sus-
penders, loafer shoes, dresses that open down the front may be used when necessary.
5 = Patient needs help in putting on, removing or fastening any clothing. He must do at least half the work himself. He must accom-
plish this in a reasonable time. Women need not be scored on use of a brassiere or girdle unless these are prescribed garments.
 
• Continence of bowels
10 = Patient is able to control his bowels and have no accidents. He can use a suppository or take an enema when necessary (as for
spinal cord injury patients who have had bowel training).
5 = Patient needs help in using a suppository or taking an enema or has occasional accidents.
 
• Controlling bladder
10 = Patient is able to control his bladder day and night. Spinal cord injury patients who wear an external device and leg bag must put
them on independently, clean and empty bag, and stay dry day and night.




Appendix 3. National Institutes of Health Stroke Scale (NIHSS)
 
Domains Items Point
1A: Level of conscious-
ness
• Alert; keenly responsive
• Arouses to minor stimulation
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• Movements to pain




1B: Ask month and age • Both questions right
• 1 question right








1C: 'Blink eyes' and
'squeeze hands'
• Performs both tasks
• Performs 1 task







• Partial gaze palsy: can be overcome
• Partial gaze palsy: corrects with oculocephalic reflex





3: Visual fields • No visual loss
• Partial hemianopia
• Complete hemianopia







4: Facial palsy • Normal symmetry
• Minor paralysis (flat nasolabial fold, smile asymmetry)
• Partial paralysis (lower face)
• Unilateral complete paralysis (upper/lower face)






5A: Le] arm motor dri] • No dri] for 10 seconds
• Dri], but doesn't hit bed
• Dri], hits bed
• Some effort against gravity
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5B: Right arm motor
dri]
• No dri] for 10 seconds
• Dri], but doesn't hit bed
• Dri], hits bed
• Some effort against gravity










6A: Le] leg motor dri] • No dri] for 5 seconds
• Dri], but doesn't hit bed
• Dri], hits bed
• Some effort against gravity










6B: Right leg motor dri] • No dri] for 5 seconds
• Dri], but doesn't hit bed
• Dri], hits bed
• Some effort against gravity










7: Limb ataxia • No ataxia
• Ataxia in 1 limb
• Ataxia in 2 limbs









8: Sensation • Normal; no sensory loss
• Mild-moderate loss: less sharp/more dull
• Mild-moderate loss: can sense being touched
• Complete loss: cannot sense being touched at all
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9: Language/aphasia • Normal; no aphasia
• Mild-moderate aphasia: some obvious changes, without significant limita-
tion
• Severe aphasia: fragmentary expression, inference needed, cannot identify
materials







10: Dysarthria • Normal
• Mild-moderate dysarthria: slurring but can be understood
• Severe dysarthria: unintelligible slurring or out of proportion to dysphasia
• Mute/anarthric










• Extinction to bilateral simultaneous stimulation
• Profound hemi-inattention (e.g. does not recognize own hand)









Appendix 4. Cochrane Central Register of Controlled Trials (Central) search strategy
IDSearchHits
#1MeSH descriptor: [Cerebrovascular Disorders] this term only 1540
#2MeSH descriptor: [Basal Ganglia Cerebrovascular Disease] this term only 11
#3MeSH descriptor: [Brain Ischemia] explode all trees 3346
#4MeSH descriptor: [Carotid Artery Diseases] this term only 493
#5MeSH descriptor: [Carotid Artery Thrombosis] explode all trees 19
#6MeSH descriptor: [Intracranial Arterial Diseases] this term only 11
#7MeSH descriptor: [Cerebral Arterial Diseases] this term only 26
#8MeSH descriptor: [Intracranial Embolism and Thrombosis] this term only 88
#9MeSH descriptor: [Stroke] explode all trees 8879
#10(isch?emi* near/6 (stroke* or apoplex* or cerebral vasc* or cerebrovasc* or cva or attack*)):ti,ab,kw (Word variations have been
searched)1931
#11((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or
middle cerebr* or mca* or anterior circulation) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*)):ti,ab,kw (Word
variations have been searched)7468
#12{or #1-#11} 18155
#13MeSH descriptor: [Choline] explode all trees 1343
#14MeSH descriptor: [Acetylcholine] this term only 461
#15MeSH descriptor: [Phosphatidylcholines] this term only 279
#16MeSH descriptor: [Dimyristoylphosphatidylcholine] explode all trees 1
#17MeSH descriptor: [1,2-Dipalmitoylphosphatidylcholine] this term only 16
#18MeSH descriptor: [Lecithins] explode all trees 47
#19MeSH descriptor: [Choline Dehydrogenase] this term only 1
#20MeSH descriptor: [Choline Kinase] this term only 1
#21(bursine or vidine or fagine or cholin*):ti,ab,kw (Word variations have been searched) 5445
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#22(benzoylcholine or chloroacetylcholine or bromoacetylcholine or carbachol or citicoline or diphosphocholine or phosphorylcholine
or propylbenzilylcholine or succinylcholine or thiocholine or acetylthiocholine or butyrylthiocholine):ti,ab,kw (Word variations have been
searched) 1781
#23(atsefen or centrophenoxine or cerutil or cetrexin or helfergin or meclofenoxate):ti,ab,kw (Word variations have been searched)41
#24MeSH descriptor: [Receptors, Cholinergic] explode all trees 281
#25((acetylcholin* or cholin*) near/5 (receptor* or site*)):ti,ab,kw (Word variations have been searched) 1439
#26cholinocep*.tw.:ti,ab,kw (Word variations have been searched) 0
#27{or #13-#26} 8203
#28#12 and #27 138
Appendix 5. MEDLINE Ovid search strategy
1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery
thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle
cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying) adj5 (isch?
emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. exp Choline/
6. acetylcholine/
7. phosphatidylcholines/ or dimyristoylphosphatidylcholine/ or 1,2-dipalmitoylphosphatidylcholine/ or lecithin/ or choline
dehydrogenase/ or choline kinase/
8. (bursine or vidine or fagine or cholin$).tw.
9. (benzoylcholine or chloroacetylcholine or bromoacetylcholine or carbachol or citicoline or diphosphocholine or phosphorylcholine or
propylbenzilylcholine or succinylcholine or thiocholine or acetylthiocholine or butyrylthiocholine).tw.
10. (atsefen or centrophenoxine or cerutil or cetrexin or helfergin or meclofenoxate).tw.
11. exp Receptors, Cholinergic/
12. exp Cholinergic Neurons/
13. ((acetylcholin$ or cholin$) adj5 (receptor$ or site$)).tw.
14. cholinocep$.tw.
15. or/5-14
16. randomized controlled trial.pt.







24. 4 and 15 and 23
Appendix 6. Embase Ovid search strategy
1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insuQiciency/ or carotid
artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle
cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. 1 or 2 or 3
5. choline derivative/ or choline/
6. citicoline/
7. acetylcholine/
8. exp glycerophospholipid/ or choline kinase/ or choline dehydrogenase/
9. (bursine or vidine or fagine or cholin$).tw.
10. (benzoylcholine or chloroacetylcholine or bromoacetylcholine or carbachol or citicoline or diphosphocholine or phosphorylcholine or
propylbenzilylcholine or succinylcholine or thiocholine or acetylthiocholine or butyrylthiocholine).tw.
11. (atsefen or centrophenoxine or cerutil or cetrexin or helfergin or meclofenoxate).tw.
12. cholinergic receptor/
13. exp cholinergic receptor stimulating agent/ or cholinergic receptor aQecting agent/
14. ((acetylcholin$ or cholin$) adj5 (receptor$ or site$)).tw.
15. cholinocep$.tw.
16. or/5-15
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17. Randomized Controlled Trial/ or "randomized controlled trial (topic)"/
18. Randomization/
19. Controlled clinical trial/ or "controlled clinical trial (topic)"/
20. control group/ or controlled study/
21. clinical trial/ or "clinical trial (topic)"/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
22. Crossover Procedure/
23. Double Blind Procedure/
24. Single Blind Procedure/ or triple blind procedure/
25. placebo/ or placebo eQect/
26. (random$ or RCT or RCTs).tw.
27. (controlled adj5 (trial$ or stud$)).tw.
28. (clinical$ adj5 trial$).tw.
29. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
30. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
31. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
33. (cross-over or cross over or crossover).tw.
34. (placebo$ or sham).tw.
35. trial.ti.
36. (assign$ or allocat$).tw.
37. controls.tw.
38. or/17-37
39. 4 and 16 and 38
Appendix 7. LILACS (Latin American and Caribbean Health Science Information database) search strategy
(tw:(citicoline)) AND (tw:(ictus))
Appendix 8. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov)
citicoline OR choline | ischaemic stroke OR brain ischaemia OR cerebral infarction OR acute stroke
Appendix 9. World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/
ictrp/en);
stroke AND citicoline OR stroke AND choline
cerebrovascular AND citicoline OR cerebrovascular AND choline
Appendix 10. Food and Drug Administration
Citicoline or cytidine 5'-diphosphocholine
Appendix 11. European Medicines Agency
Citicoline or cytidine 5'-diphosphocholine
Appendix 12. Domains for assessing of risk of bias in included studies
Generation of the allocation sequence
• Low risk of bias, if the allocation sequence was generated by a computer or random number table, drawing of lots, tossing of a coin,
shuQling of cards or throwing dice.
• Unclear, if the trial was described as randomized but the method used for the allocation sequence generation was not described.
• High risk of bias, if a system involving dates, names or admittance numbers was used for the allocation of patients. These studies are
known as quasi-randomized and we excluded them from the review.
Allocation concealment
• Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, identical-appearing
numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.
• Unclear, if the trial was described as randomized but the method used to conceal the allocation was not described.
• High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-
randomized. We excluded the latter from the review.
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Blinding (or masking)
We assessed each trial (as low, unclear or high risk) with regard to the following levels of blinding.
• Blinding of clinician (person delivering treatment) to treatment allocation.
• Blinding of participant to treatment allocation.
• Blinding of outcome assessor to treatment allocation.
Incomplete outcome data
• Low risk of bias, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or it was specified
that there were no dropouts or withdrawals.
• Unclear, if the report gave the impression that there had been no dropouts or withdrawals but this was not specifically stated.
• High risk of bias, if the number or reasons for dropouts and withdrawals were not described.
We further examined the percentage of dropouts overall in each trial and per randomization arm and we evaluated whether intention-to-
treat analysis was performed or could be performed from the published information.
Selective outcome reporting
• Low risk of bias, if predefined or clinically relevant and reasonably expected outcomes were reported on.
• Unclear, if not all predefined or clinically relevant and reasonably expected outcomes were reported on or were not reported on fully,
or it was unclear whether data on these outcomes were recorded or not.
• High risk of bias, if one or more clinically relevant and reasonably expected outcomes were not reported on when data on these
outcomes were likely to have been recorded.
Other bias
• Low risk of bias, the trial appeared to be free of other components that could put it at risk of bias.
• Unclear, the trial may or may not be free of other components that could put it at risk of bias.
• High risk of bias, there were other factors in the trial that could put it at risk of bias.
We will consider trials at low risk of bias to be those that used an adequate system to generate their allocation sequence, had adequate
allocation concealment, adequate blinding, adequate handling of incomplete outcome data, were free of selective outcome reporting and
were free of other bias.
We will consider trials in which we could assess one of the domains as having a high risk of bias or an unclear risk of bias as trials with
an overall high risk of bias.
Appendix 13. Method for grading levels of impaired consciousness, according to Japanese Coma Scale
 
Grade Description





Patient spontaneously awake but
Obtunded or confused
Disoriented to time, place, and person





Patient may be aroused, but falls into drowsy state after cessation of stimulation
Easily aroused by spoken words
Aroused by loud voice or shaking the shoulders
Aroused only by repeated stimuli
III Patient cannot be aroused by painful stimuli
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Responds by movement to avoid stimulus
Responds with minimal movement such as decerebrate and decorticate posturing




F E E D B A C K
New Feedback, October 2020
Summary
There are some mistakes in the publication, specifically on the labelling of the results for citicoline and placebo in the Forest Plots of the
analysis 1.8 to 1.13 related to the modified Rankin scale (pages 60 to 63), the analysis 1.16 of the Barthel Index and the analysis 1.17 of the
NIHSS (page 68). A modified Rankin scale (< 3 points), a Barthel Index (≥ 95 points) and a NIHSS (≤ 1 point) are positive outcomes and the
results of the clinical trials included in this meta-analysis at least tend to favor citicoline, not placebo. In the current publication, results of
this scales indicate to favor placebo, which is just the contrary. Most probably the legend on the base of the plot’s is in a wrong position.
There is a relevant diQerence between favours placebo rather than favours citicoline, that at the end distorts reality and compromises the
content of the article, despite this could involve also a mistake in the interpretation of the results We consider that these errors are serious
and should be corrected and/or commented immediately.
Reply
We thank Dr Emilio Gil for the interest in our review and the feedback provided. We appreciate his detailed comment, which contributed to
identify a formal error (namely, a mistake in the legend of a set of forest plots) and also highlighted some issues about the interpretation
of the results.
We have addressed the comments provided by Dr Gil and have provided an amended version of the review to ensure that the errors were
fixed. We additionally revised the text of the review to ensure that its findings and conclusions were framed to avoid ambiguous or equivocal
messages.
The conclusions for the review in the current version are consistent with its findings, taking into account the quality of evidence and the
clinical magnitude of the results obtained, and has not changed in relation to the version originally published.
The consistent low certainty of evidence across all outcomes and the clinically irrelevant eQects of citicoline support our conclusion that
citicoline may make little to no diQerence in any of the patient important outcomes assessed.
We provide here a detailed account of the amendments done in the review that should serve as a response to Dr Gil.
Revision of graphs labels from analysis 1.8 to 1.13, 1.16 and 1.17
As Dr Gil pointed out the labels for the plots from the outcomes related to disability, functional recovery and neurological function are
incorrect. As these outcomes are positive the right panel of the plots shows a result favouring citicoline, whereas the le] panel shows a
result favouring placebo.
Action: we switched the graph labels of the plots in these analyses (in the current version graph labels are ‘Favours citicoline’ for the forest
plot right panel, and ‘Favours placebo’ for the le] panel).
Clarification of the outcomes
To avoid an equivocal definition of outcomes and to better reflect what was measured in the review we decided to reword the outcomes
related to disability, functional recovery and neurological function. We defined these outcomes as dichotomous, as in consequence they
should be described in terms of the proportion of patients that attained the outcome during the trial. This change entails strictly a change
in the name of the outcome, but it does not have an impact on the data extracted, statistical analyses, and interpretation of results or the
review conclusions.
Action: we changed the outcomes wording both in the review text and in the included figures. We reworded the outcomes for analysis 1.8
to 1.13, 1.16 and 1.17 (e.g., the new wording for analysis 1.8. in the current version is “Patients with moderate or lower degree of disability
or dependence (according to < 3 scores in the modified Rankin scale)”
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Changes in the wording of review findings
As a consequence of the changes related to the issues stated above, we also revised the wording of review findings and conclusions to better
reflect the measurement approach for the outcomes related to disability, functional recovery and neurological function in our review. We
followed a novel approach to communicate the findings of systematic reviews through informative statements combining eQect size and
certainty of an outcome (Santesso J, Clinical Epidemiology, 2020, https://doi.org/10.1016/j.jclinepi.2019.10.014). By implementing this
approach we are convinced that the statements should not leave room for doubt about the magnitude of the eQects found in the review.
Action: we worded the findings of the review according to this new approach and amended accordingly the abstract and plain language
summary (e.g.; the original text “Four trials found no diQerence in the proportion of patients with disability or dependence in daily activities
according to the Rankin scale comparing citicoline with placebo” changed to “Four trials showed that citicoline may not increase the
proportion of patients with a moderate or lower degree of disability or dependence compared with placebo”.
Revision of trial sequential analysis
We reviewed the wording of findings related to the TSA for disability to ensure that were accurate.
Minor amendments in the 'Results' section and additional typos
We did some editing through the review results, mainly those related to the reporting of subgroup analyses related to disability, to ensure
that interpretation of results is consistent with the outcome definition. For example:
• we changed the original “meta-analysis of two trials reporting missing data showed a reduction of 56% of risk of disability or
dependence in people receiving citicoline versus control (RR 0.44, 95% CI 0.39 to 0.51; IP = 67%)” to “meta-analysis of two trials reporting
missing data showed that citicoline may result in a slight reduction in the proportion of patients with a moderate or lower degree of
disability or dependence compared with placebo (RR 0.44, 95% CI 0.39 to 0.51; IP = 67%)”;
• in the subgroup analysis according the trials sample size for disability, we changed the original “A meta-analysis including three trials
showed no diQerence comparing citicoline with placebo as regards degree of disability or dependence in daily activities” to “A meta-
analysis including the three trials which included more than 200 participants showed that citicoline may result in little or no diQerence
in the proportion of patients with a moderate or lower degree of disability or dependence compared with placebo”;
• in the sensitivity analysis assessing the impact of missing data there was a copy edit error in the CI95% boundaries (lower limit 1.01
instead of 1.00)
Contributors
Feedback: Emilio Gil, Ferrer International
Authors' response: Review author team
W H A T ' S   N E W
 
Date Event Description
7 December 2020 Feedback has been incorporated Feedback and authors' responses added
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Arturo Martí-Carvajal: none known.
Claudia Valli: none known.
Cristina Martí-Amarista: none known.
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S O U R C E S   O F   S U P P O R T
Internal sources
• Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE (Cochrane Ecuador), Quito, Ecuador
• Facultad de Medicina, Universidad Francisco de Vitoria (Cochrane Madrid), Madrid, Spain
External sources
• Cochrane Stroke Group, UK
• Iberoamerican Cochrane Network, Spain, Spain
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
• Disability or dependence in daily activities (< 3 points) according to the modified Rankin scale. Usually, RCTs use 1 or less than 1.
However, we used less than 3 to avoid ruling out one trial that used this cut-oQ point. This threshold was discussed with our team's
neurologist who agreed with our approach.
• We did not conduct estimation of the fragility index (FI) due to lack of data. For future updates, we will conduct it as was planned.
• Transparency is the goal. If we had strictly assumed the 90th day to carry out the meta-analyses, we would have lost a lot of information.
Therefore, this Cochrane Review would have a high risk of publication bias.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Activities of Daily Living;  Acute Disease;  Bias;  Brain Ischemia  [complications];  Cause of Death;  Cytidine Diphosphate Choline  [adverse
eQects]  [*therapeutic use];  Nootropic Agents  [adverse eQects]  [*therapeutic use];  Randomized Controlled Trials as Topic;  Recovery of
Function;  Stroke  [*drug therapy]  [etiology]  [mortality]
MeSH check words
Aged; Aged, 80 and over; Humans; Middle Aged
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